

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number  
WO 01/97850 A2

(51) International Patent Classification<sup>7</sup>: A61K 45/06

(21) International Application Number: PCT/EP01/06976

(22) International Filing Date: 20 June 2001 (20.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
00250194.8 23 June 2000 (23.06.2000) EP  
00250214.4 28 June 2000 (28.06.2000) EP

(71) Applicant: SCHERING AKTIENGESELLSCHAFT  
[DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).

(71) Applicants and

(72) Inventors: SIEMEISTER, Gerhard [DE/DE]; Reimerswalder Steig 26, 13503 Berlin (DE). HABEREY, Martin [DE/DE]; Steinstr. 1, 12169 Berlin (DE). THIERAUCH, Karl-Heinz [DE/DE]; Hochwildpfad 45, 14169 Berlin (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF AND ANGIOPOIETIN/TIE RECEPTOR FUNCTION AND THEIR USE (I)

(57) Abstract: The present invention describes the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

A3



WO 01/97850 A2

**Combinations and compositions which interfere with VEGF/ VEGF and  
angiopoietin/ Tie receptor function and their use (II)**

5 The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

10

Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their  
15 receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of  
20 the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PlGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an  
25 orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonpierre et al., Science 277, 55-60, 1997; Valenzuela et al., Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

30

The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442,

1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al. *Nature* 376, 62-66, 1995), whereas Flt1  
5 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during  
10 early development of the cardiovascular system (Dumont et al., *Science* 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., *Science* 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce  
15 neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., *Proc. Natl. Acad. Sci. USA* 95, 14389-14394, 1998).

The second class of endothelial cell specific receptor tyrosine kinases has also  
20 been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., *Nature* 376, 70-74, 1995; Rodewald & Sato, *Oncogene* 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and  
25 lacking periendothelial support cells (Sato et al., *Nature* 376, 70-74, 1995; Dumont et al., *Genes Dev.* 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonpierre et al., *Science* 277, 55-60, 1997; Suri et al., *cell* 87, 1171-1180). Conversely, increased vascularization was  
30 observed upon transgenic overexpression of Ang1 (Suri et al., *Science* 282, 468-471, 1998; Thurston et al., *Science* 286, 2511-2514, 1999).

The results from angiogenic growth factor expression studies in corpus luteum development (Maisonpierre et al., *Science* 277, 55-60, 1997; Goede et al. *Lab.*

Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al, Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of endothelial-peri endothelial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine kinase (Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., Cancer Res. 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al., Cancer Res. 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of

VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., J. Clin. Invest. 103, 159-165, 1999).

10 The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kaipainen et al., Cancer Res. 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., Br. J. Cancer 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., Cancer Res. 56, 1615-1620, 1996), as well as elevated expression of Flt4  
15 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., Cancer Res. 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., Am. J. Pathol. 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high  
20 upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2  
25 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., Science 284, 1994-1998, 1999; Holash et al., Oncogene 18, 5356-5362, 1999).

Interference with Tie2 receptor function by means of Angiopoietin-neutralizing  
30 Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al. Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Comparing the effects of interference with the endothelium-specific receptor

tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60, 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.

Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-peri-endothelial cell interaction of existing mature tumor vessels and thereby sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with

Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or

5 consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of

10 Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or of the

Angiopoietin/Tie receptor systems and compound II consists of cytotoxic agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems.

Targeting or modulation of the biological activities of VEGF/VEGF receptor

15 systems and of Angiopoietin/Tie receptor systems can be performed by

(a) compounds which inhibit receptor tyrosine kinase activity,

(b) compounds which inhibit ligand binding to receptors,

(c) compounds which inhibit activation of intracellular signal pathways of the  
20 receptors,

(d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,

(e) delivery systems, such as antibodies, ligands, high-affinity binding  
oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents  
25 or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,

(f) delivery systems, such as antibodies, ligands, high-affinity binding  
oligonucleotides or oligopeptides, or liposomes, which are targeted to the  
endothelium and induce necrosis or apoptosis.

30 A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine

kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), *Cancer Res.* 59, 99-106; Vajkoczy et al., *Proc. Am. Associ. Cancer Res. San Francisco* (2000), Abstract ID 3612; Zeneca: ZD4190, ZD6474; Wedge et al. (2000), *Cancer Res.* 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., *Proc. Am. Associ. Cancer Res., San Francisco* (2000), Abstract ID 3614; Dimitroff et al. (1999), *Invest. New Drugs* 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as *Pseudomonas* exotoxin A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhuMAbVEGF) and by Presta et al. (1997), *Cancer Res.* 57, 4593-4599. Ligand-binding receptor domains are described by Kendall & Thomas (1993), *Proc. Natl. Acad. Sci., U.S.A.* 90, 10705-10709; by Goldman et al. (1998) *Proc. Natl. Acad. Sci., U.S.A.* 95, 8795-8800 and by Lin et al. (1997), *J. Clin. Invest.* 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), *Nature* 367, 567-579. Receptor blocking antibodies have been described by Imclone (c-p1C11, US 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), *Proc. Natl. Acad. Sci., U.S.A.* 95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), *Nat. Biotech* 14, 1021-1025. Further, small molecules and peptides have been described.


Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).



Examples for delivery-/Targeting-Systems have been described as ligand/  
antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59,  
183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothel cell  
targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci, U.S.A94, 8795-  
5 8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998),  
Cancer Res. 58, 4646-4653).

10 Small molecules which inhibit the receptor tyrosine kinase activity are for example  
molecules of general formula I

15



20

in which

r has the meaning of 0 to 2,


n has the meaning of 0 to 2;

25

R<sub>3</sub> und R<sub>4</sub> a) each independently from each other have the meaning  
of lower alkyl,


9

b) together form a bridge of general partial formula II,



wherein the binding is via the two terminal C- atoms, and has the meaning of 0 to 4; or

c) together form a bridge of partial formula III



wherein one or two of the ring members  $T_1, T_2, T_3, T_4$  has the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms  $T_1$  and  $T_4$ ;

has the meaning of  $C_1 - C_6$  - alkyl,  $C_2 - C_6$  - alkylene or  $C_2 - C_6$  - alkenylene; or  $C_2 - C_6$  - alkylene or  $C_3 - C_6$  - alkenylene, which are substituted with acyloxy or hydroxy;  $-CH_2-O-$ ,  $-CH_2-S-$ ,  $-CH_2-NH-$ ,  $-CH_2-O-CH_2-$ ,  $-CH_2-S-CH_2-$ ,  $-CH_2-NH-CH_2$ , oxa ( $-O-$ ), thia ( $-S-$ ) or imino ( $-NH-$ ),

independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

Q has the meaning of lower alkyl, lower alkyloxy or halogene,  
R<sub>1</sub> and R<sub>2</sub> independently from each other have the meaning of H or lower alkyl,

X has the meaning of imino, oxa or thia;

5 Y has the meaning of hydrogene, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated  
10 carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if  
15 more than one rest Z is present ( $m \geq 2$ ), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single or double bonds; or an N-oxide of said compound, wherein one ore more N-atoms carry an oxygene atom, or a salt thereof.

20

A preferred salt is the salt of an organic acid, especially a succinate.

These compounds can preferentially be used as compound I or II in the inventive pharmaceutical composition.


25

Compounds which stop a tyrosin phosphorylation, or the persistent angiogenese, respectively, which results in a prevention of tumor growth and tumor spread, are for example

anthranil acid derivatives of general formula IV

30

11



in which

A


has the meaning of group  $=NR^2$ ,

W


has the meaning of oxygen, sulfur, two hydrogen atoms or the group  $=NR^8$ ,

Z

has the meaning of the group  $=NR^{10}$  or  $=N-$ ,  $-N(R^{10})-$ ,  $(CH_2)_q$ , branched or unbranched  $C_{1-6}$ -Alkyl or is the group



or A, Z and  $R^1$  together form the group



m, n and o

q

R<sub>a</sub>, R<sub>b</sub>, R<sub>c</sub>, R<sub>d</sub>, R<sub>e</sub>, R<sub>f</sub>

5

X

Y

p

R<sup>1</sup>

15

R<sup>2</sup>

20

R<sup>3</sup>

25

R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup>

has the meaning of 0 – 3,

has the meaning of 1 – 6,

independently from each other have the meaning of hydrogen, C<sub>1-4</sub> alkyl or the group =NR<sup>10</sup>, and/or R<sub>a</sub> and/or R<sub>b</sub> together with R<sub>c</sub> and/or R<sub>d</sub> or R<sub>c</sub> together with R<sub>a</sub> and/or R<sub>f</sub> form a bound, or up to two of the groups R<sub>a</sub>-R<sub>f</sub> form a bridge with each up to 3 C-atoms with R<sup>1</sup> or R<sup>2</sup>,

has the meaning of group =NR<sup>9</sup> or =N-,

has the meaning of group -(CH<sub>2</sub>)<sub>p</sub>,

has the meaning of integer 1-4,


has the meaning of unsubstituted or optionally substituted with one or more of halogene, C<sub>1-6</sub>-alkyl, or C<sub>1-6</sub>-alkyl or C<sub>1-6</sub>-alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,

has the meaning of hydrogen or C<sub>1-6</sub>-alkyl, or form a bridge with up to 3 ring atoms with R<sub>a</sub>-R<sub>f</sub> together with Z or R<sub>1</sub>,

has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of fur halogen, C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkoxy or hydroxy,

independently from each other have the meaning of hydrogen, halogen or C<sub>1-6</sub>-alkoxy, C<sub>1-6</sub>-alkyl or


C<sub>1-6</sub>-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or R<sup>5</sup> and R<sup>6</sup> together form the group



- 5 R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> independently from each other have the meaning of hydrogen or C<sub>1-6</sub>-alkyl, as well as their isomers and salts.

10 These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical composition.

More preferentially compounds of general formula V




V,



15 in which

R<sup>1</sup> has the meaning of group





20




14



in which  $R^5$  is chloro, bromo or the group  $-OCH_3$ ,



in which  $R^7$  is  $-CH_3$  or chloro,




in which  $R^8$  is  $-CH_3$ , fluoro, chloro or  $-CF_3$

in which  $R^4$  is fluoro, chloro, bromo,  $-CF_3$ ,  $-N=C$ ,  $-CH_3$ ,  $-OCF_3$  or  $-CH_2OH$

in which  $R^6$  is  $-CH_3$  or chloro

$R^2$

has the meaning of pyridyl or the group



and

$R^3$

has the meaning of hydrogen or fluoro, as well as their isomers and salts can be used as compound I or II in the inventive pharmaceutical composition.

These compounds have the same properties as already mentioned above under compound IV and can be used for the treatment of angiogeneous diseases.

Compositions comprise compounds of general formulars I, IV and V, alone or in combination.

The above mentioned compounds are also claimed matter within the inventive combinations.

A further example for ligand binding inhibitors are peptides and DNA sequences coding for such peptides, which are used for the treatment of angiogeneous diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59 of the sequence protocol. It has been shown that Seq. ID Nos. 34 and 34a are of main interest.

Claimed matter of the instant invention are therefor pharmaceutical compositions



a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

5

b) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

10

c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,

15

d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

20

e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

25

f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,

30

g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

5

For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately .

The inventive compositions comprise as compound I or as compound II at least one of

10

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- 15 d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of
- 20 VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

These compositions are also claimed matter of the present invention.

25

Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims

30

which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

- 5 The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.

Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-

- 10 pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate; sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred  
15 pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical  
20 compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35; pharmaceutical compositions, which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

- The small molecule compounds, proteins and DNA's expressing proteins, as  
25 mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome,  
30 transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no

scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

Further, the inventive combinations can be used for suppression of the ascites formation in patients. It is also possible to suppress VEGF oedemas.

For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch, magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/ or buffer.

These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/ or hydrocarbon carriers or binders, such as lactose, maize or potato starch. The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg. The dosis can be applied as single dose or as two or more daily dosis.

These formulations and application forms are also part of the instant invention.

- Combined functional interference with VEGF/VEGF receptor systems and with
- 5   Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to interference with one ligand/receptor system overlaps with the biological response to interference with a second ligand/receptor system. Alternatively, combined functional interference with VEGF/VEGF receptor systems or with Angiopoietin/Tie receptor systems and
- 10   targeting of cytotoxic agents via VEGF/VEGF receptor systems or via Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to functional interference with a ligand/receptor system overlaps in time with targeting of cytotoxic agents.
- 15   The invention is also directed to a substance which functional interferes with both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems, or which are targeted via both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems.
- 20   VEGF/VEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C, VEGF-D, PlGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2 (KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1). Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor
- 25   tyrosine kinases Tie1 and Tie2.

Pharmaceutical compositions of the present invention can be used for medicinal purposes. Such diseases are, for example, cancer, cancer metastasis, angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of

30   the present invention can be applied orally, parenterally, or via gene therapeutic methods.

Therefor the present invention also concerns the use of pharmaceutical compositions for the production of a medicament for the treatment of tumors,

cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

The following examples demonstrate the feasibility of the disclosed invention, without restricting the invention to the disclosed examples.

### 5 Example 1

Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

10

Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector (A375v/pCEP). Swiss *nu/nu* mice were s.c. injected with  $1 \times 10^6$  transfected A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

15

20

Table 1

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm<sup>2</sup> (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or separate interference with Angiopoietin/Tie2 receptor system by means of
- 10 expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm<sup>2</sup> to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I + compound II, treatment group 4) delayed growth of the
- 15 tumors to a size of approx. 250 mm<sup>2</sup> to 38 days.

This result clearly demonstrates the superior effect of a combination of interference with the VEGF-A/VEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.



**Example 2**

Combination of functional interference with the Angiopoietin/Tie2 receptor system and neutralization of VEGF-A is superior to separate modes of intervention in  
 5 inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated twice weekly over a period of time of 4 weeks with intraperitoneal doses of  
 10 200 µg of the VEGF-A-neutralizing monoclonal antibody (mAb) 4301-42-35 (Schlaeppli et al., J. Cancer Res. Clin. Oncol. 125, 336-342, 1999). Various modes of treatment are descibed in Table 2. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its  
 15 perpendicular.

Table 2

treatment group	mode of treatment	
	mAb 4301-42-35 (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000  
 20 mm<sup>3</sup> within 28 days (Figure 2) without treatment (group 1). Tumors treated with the VEGF-A-neutralizing mAb 4301-42-35 (compound I, treatment group 2) grew to a volume of approx. 450 mm<sup>3</sup> within 28 days. Interference with

Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm<sup>2</sup>, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and neutralizing of VEGF-A by means of  
5 the mAb 4301-42-35 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm<sup>3</sup> within 28 days.

The superior effect of a combination of neutralization of VEGF-A and functional  
10 interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

**Example 3**

Combination of functional interference with the Angiopoietin/Tie2 receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

5

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A single chain antibody (scFv)

specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) was expressed in *E. coli* and conjugated to coagulation-inducing

10 recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx.

200 mm<sup>3</sup> animals receiving compound I were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 3. Animals were sacrificed for ethical reasons

15 when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 3

treatment group	mode of treatment	
	scFv-tTF conjugate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 3) without treatment (group 1). Tumors treated with the coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound I, treatment group 2) grew to a volume of approx. 500 mm<sup>3</sup> within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm<sup>2</sup>, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 300 mm<sup>3</sup> within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to VEGF/VEGF receptor systems.

**Example 4**

Combination of functional interference with the VEGF/VEGF receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of a single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) which was expressed in *E. coli* and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm<sup>3</sup> animals receiving compound II were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 4. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 4

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	scFv-tTF conjugate (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 4) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm<sup>3</sup>. Tumors treated with the
- 10 coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound II, treatment group 3) grew to a volume of approx. 500 mm<sup>3</sup> within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex
- 15 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 400 mm<sup>3</sup> within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the

20 VEGF/VEGF receptor system over separate modes of intervention is clearly

shown. Similar effects can be expected upon targeting of cytotoxic agents to Angiopoietin/Tie receptor systems.

**Example 5**

Combination of functional interference with the Angiopoietin/Tie2 receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to  
 5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A fusion protein (L19 scFv-tTF) consisting of L19 single chain antibody specifically recognizing the oncofoetal ED-  
 10 B domain of fibronectin and the extracellular domain of tissue factor was expressed in E. coli as described by Nilsson et al. (Nat. Med., in press). Further, L19 scFv-tTF data have been represented by D. Neri and F. Nilsson (Meeting "Advances in the application of monoclonal antibodies in clinical oncology", Samos, Greece, 31. May-2. June 2000). When tumors reached a size of approx.  
 15 200 mm<sup>3</sup> animals receiving compound I were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 5. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 5

treatment group	mode of treatment	
	L19 scFv-tTF (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+



Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 5) without treatment (group 1). Tumors treated with the coagulation-inducing L19 scFv-tTF (compound I, treatment group 2) grew to a volume of approx. 450 mm<sup>3</sup> within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm<sup>2</sup>, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the endothelium with L19 scFv-tTF (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm<sup>3</sup> within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

**Example 6**

Combination of functional interference with the VEGF/VEGF receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to  
5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-  
10 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of L19 scFv-tTF fusion protein as described in example 5. When tumors reached a size of approx. 200 mm<sup>3</sup> animals receiving compound II were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of  
15 treatment are described in Table 6. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 6

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)- phthal-azin-1-yl]ammonium hydrogen succinate  (compound I)	L19 scFv-tTF (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

5

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 6) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm<sup>3</sup>. Tumors treated with the coagulation-inducing L19 scFv-tTF targeted to the endothelium (compound II, treatment group 3) grew to a volume of approx. 450 mm<sup>3</sup> within 28 days.

10

Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 200 mm<sup>3</sup> within 28 days.

15

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly shown.

5

10

### Description of the figures

Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of a specific tyrosine kinase inhibitor and with the Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1).

The abbreviations have the following meaning:

	mock, con.	=	treatment group 1
	mock+VEGF-A	=	treatment group 2
10	sTIE2-cl13	=	treatment group 3
	sTIE2-cl13+VEGF-A	=	treatment group 4

Fig. 2 shows the superior effect on tumor growth inhibition of combination of VEGF-neutralization and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 2).

Fig. 3 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 3).

Fig. 4 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 4).

Fig. 5 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 5).

Fig. 6 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 6).

## CLAIMS

1. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF  
5 receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
2. Pharmaceutical compositions comprising one or several agents as compound I  
10 which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
- 15 3. Pharmaceutical compositions comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium.  
20
4. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which  
25 are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
5. Pharmaceutical compositions comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which  
30 are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
6. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF

receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems.

- 5 7. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
- 10 8. Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.
- 15 9. Pharmaceutical compositions according to claims 1-8 which are intended for simultaneous or separate sequential therapeutical application.
10. Pharmaceutical compositions according to claims 1-8 which comprise as compound I at least one of
- 20 a) compounds which inhibit receptor tyrosine kinase activity,  
b) compounds which inhibit ligand binding to receptors,  
c) compounds which inhibit activation of intracellular signal pathways of the receptors,  
d) compounds which inhibit or activate expression of a ligand or of a  
25 receptor of the VEGF or Tie receptor system,  
e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor  
30 systems,  
f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.



11. Pharmaceutical compositions according to claims 1-8 which comprise as compound II at least one of

- g) compounds which inhibit receptor tyrosine kinase activity,
- h) compounds which inhibit ligand binding to receptors,
- 5 i) compounds which inhibit activation of intracellular signal pathways of the receptors,
- j) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- 10 k) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- 15 l) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.


12. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

13. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II Seq. ID Nos. 34a

14. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTFconjugate.

15. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one small molecule of general formula I

41



I,

in which

5

r

has the meaning of 0 to 2,

n


has the meaning of 0 to 2;

 $R_3$  und  $R_4$ 

a) each independently from each other have the meaning of lower alkyl,

10

b) together form a bridge of general partial formula II,



II,

15


wherein the binding is via the two terminal C- atoms,  
and

m

has the meaning of 0 to 4; or

c) together form a bridge of partial formula III

20



has

wherein one or two of the ring members  $T_1, T_2, T_3, T_4$  the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms  $T_1$  and  $T_4$ ;

G

has the meaning of  $C_1 - C_6$  - alkyl,  $C_2 - C_6$  - alkylene or  $C_2 - C_6$  - alkenylene; or  $C_2 - C_6$  - alkylene or  $C_3 - C_6$  - alkenylene, which are substituted with acyloxy or hydroxy;  $-CH_2-O-$ ,  $-CH_2-S-$ ,  $-CH_2-NH-$ ,  $-CH_2-O-CH_2-$ ,  $-CH_2-S-CH_2-$ ,  $-CH_2-NH-CH_2$ , oxa (-O-), thia (-S-) or imino (-NH-),

A, B, D, E and T

independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

Q

has the meaning of lower alkyl, lower alkyloxy or halogene,

$R_1$  and  $R_2$

independently from each other have the meaning of H or lower alkyl,

X

has the meaning of imino, oxa or thia;

Y


has the meaning of hydrogene, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z

has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if more than one rest Z is present ( $m \geq 2$ ), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single

or double bonds; or an N-oxide of said compound,  
 wherein one or more N-atoms carry an oxygen atom,  
 or a salt thereof,

and/or a compound of general formula IV



in which

A


has the meaning of group  $=NR^2$ ,

W


has the meaning of oxygen, sulfur, two hydrogen atoms  
 or the group  $=NR^8$ ,

Z

has the meaning of the group  $=NR^{10}$  or  $=N-$ ,  $-N(R^{10})-$ ,  
 $(CH_2)_q-$ , branched or unbranched  $C_{1-6}$ -Alkyl or is the  
 group



or A, Z and  $R^1$  together form the group



m, n and o

q

R<sub>a</sub>, R<sub>b</sub>, R<sub>c</sub>, R<sub>d</sub>, R<sub>e</sub>, R<sub>f</sub>

has the meaning of 0 – 3,

has the meaning of 1 – 6,

independently from each other have the meaning of hydrogen, C<sub>1-4</sub> alkyl or the group =NR<sup>10</sup>, and/or R<sub>a</sub> and/or R<sub>b</sub> together with R<sub>c</sub> and/or R<sub>d</sub> or R<sub>c</sub> together with R<sub>e</sub> and/or R<sub>f</sub> form a bound, or up to two of the groups R<sub>a</sub>-R<sub>f</sub> form a bridge with each up to 3 C-atoms with R<sup>1</sup> or R<sup>2</sup>,

X

Y

P

R<sup>1</sup>

has the meaning of group =NR<sup>9</sup> or =N-,

has the meaning of group -(CH<sub>2</sub>)<sub>p</sub>,

has the meaning of integer 1-4,

has the meaning of unsubstituted or optionally substituted with one or more of halogene, C<sub>1-6</sub>-alkyl, or C<sub>1-6</sub>-alkyl or C<sub>1-6</sub>-alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,

R<sup>2</sup>

has the meaning of hydrogen or C<sub>1-6</sub>-alkyl, or form a bridge with up to 3 ring atoms with R<sub>a</sub>-R<sub>f</sub> together with Z or R<sub>1</sub>,


R<sup>3</sup>

has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally

$R^4, R^5, R^6$  and  $R^7$

substituted with one or more of für halogen,  $C_{1-6}$ -alkyl,  $C_{1-6}$ -alkoxy or hydroxy,


independently from each other have the meaning of hydrogen, halogene or  $C_{1-6}$ -alkoxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogene, or  $R^5$  and  $R^6$  together form the group



$R^8, R^9$  and  $R^{10}$

independently from each other have the meaning of hydrogen or  $C_{1-6}$ -alkyl, as well as their isomers and salts,

and/ or a compound of general formula V.






V,

in which


$R^1$  has the meaning of group

46




in which  $R^5$  is chloro, bromo or the group  $-OCH_3$ ,

5



in which  $R^7$  is  $-CH_3$  or chloro,




in which  $R^8$  is  $-CH_3$ , fluoro, chloro or  $-CF_3$

in which  $R^4$  is fluoro, chloro, bromo,  $-CF_3$ ,  $-N=C$ ,  $-CH_3$ ,  $-OCF_3$  or  $-CH_2OH$

in which  $R^6$  is  $-CH_3$  or chloro

$R^2$

has the meaning of pyridyl or the group



and

$R^3$

has the meaning of hydrogen or fluoro, as well as their isomers and salts.

16. Pharmaceutical compositions according to claim 15 which comprise as compound I and/ or II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

17. Pharmaceutical compositions according to claims 1-16 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II.

18. Pharmaceutical compositions according to claims 1-17 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium



hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

- 5 19. Pharmaceutical compositions according to claims 1-17 which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.
- 10 20. Pharmaceutical compositions according to claims 1-17 which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.
21. Pharmaceutical compositions according to claims 1-17 which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.
- 15 22. Use of pharmaceutical compositions according to claims 1-21, for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant
- 20 nephrosclerosis, thrombic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.




Fig. 1




Fig. 2





Fig. 3

**Fig. 4**




Fig. 5




Fig. 6

## Sequence Identifier

5

&lt;110&gt; Schering Aktiengesellschaft

10

&lt;120&gt; Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use II

&lt;130&gt; 51867AEPM1XX00-P

15

&lt;140&gt;

&lt;141&gt;

&lt;160&gt; 59

20

&lt;210&gt; 1

&lt;211&gt; 1835

&lt;212&gt; DNA

&lt;213&gt; Human

25

&lt;400&gt; 1

30

```
ttttacagtt ttccttttct tcagagttta ttttgaattt tcatttttgg ataaccaagc 60
agctctttta gaagaatgca cagaagagtc attctggcac ttttggatag tacataagat 120
tttctttttt ttttttaaat tttttttaat agtcacattc agctcgcttg ctcaaaccag 180
actcccatat tgggtgagca agatgagccc ataggattcc agagttaata cgtaaccgta 240
tatacaaca gccaaaaaac cataatggty ccacagggat ggagcagga agggcatctc 300
taacgtgtcc tctagtctat cticgctaaa cagaacccac gttacacatg ataactagag 360
agcacactgt gttgaaacga ggatgctgac cccaaatggc acttggcagc atgcagttta 420
aagcaaaaga gacatccttt aataactgta taaaatccag gcagttccat taaaggggtt 480
aagaaaaacca acaacaacaa aaagcgaggg actgtctggt gtcactgtca aaaaggcact 540
tggagttaat gggaccagga ttggaggact cttagctgat acagatttca gtacgatttc 600
attaaaaggc ttggatgta agagaggaca ctcagcgggt cctgaaggga gacgctgaga 660
tggaccgctg agaagcggaa cagatgaaca caaaggaatc aaatctttac aaccaaattg 720
catttaagcg acaacaaaaa aaggcaaac ccacaaacgca acctaacca agcaaatct 780
aagcaaaatc agacaacgaa gcagcgatgc atagctttcc tttgagagaa cgcatacctt 840
gagacgctac gtgccaacct aagttctcaa cgacagcttc acagtaggat tattgtgata 900
aaaatgactc aagcgatgca aaaagtttca tctgttccca gaatccgagg gagaactgag 960
gtgatcgta gagcatagcg acatcacgtg cggtttctta atgtccctgg tggcggatac 1020
gccgagtcct cgggaaggaca tctggacacc actttcagcc acctccttgc aggggcgaca 1080
tccgccaaag tcatccttta ttccgagtaa taactttaat tcctttctaa catttacacg 1140
gcaaacagga atgcagtaaa cgtccacgtc cgtcccacgg ctgggctgcc gttccgtttc 1200
ctccacgaac gggtagcgcg ttccatgaga aaggatattt ggcaatttta tattccacag 1260
tcaggtgggt ctgcgatagc tcatttaatg ttaaaccgca tcaggggcct ctctcccgt 1320
ttctgccagg ggcttttctt gtcttctcct tggcgagctc gtgggcagat cttctctggt 1380
gggggctggc tgctggctcc gagggggcat ccgcagtcg tctggctgct tcctcctgca 1440
ggctgggcag ctggccacca cttctccgac tcgacccctc caacaagcat cgcagggcac 1500
tgtctcggg ggtacagacc gtggtccac attcgctacc actctgttcc acgtcatcca 1560
ggtacacgag ctgcgtgtag gccgtgctgt ctggggctcg aggtctttt tgctggtgct 1620
cttgacggg cgggtagttc tgctgcagag acaaagcatc tccccttccc ttccgggctg 1680
attttggttc attcatatct acgccagagt ccaaactggc atcattactt ccgttccttc 1740
cagctctttg gagaatcaat gtatgaatgt ctaacctgac cgttggaact gccatccaag 1800
gagacgaacc acgccgggg gtgcggaagc ggcct
```

60

&lt;210&gt; 2

&lt;211&gt; 581

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 2

5 gttctagatt gttttattca gtaattagct ctttaagaccc ctggggcctg tgctacccag 60  
 aactaaciaa cagtctctat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120  
 tcaacttact tcctgtggcc cattagggaa gtggtgacct cgggagctat ttgctgttg 180  
 agtgcacaca cctggaaaca tactgtctctc attttttcat ccacatcagt gagaaatgag 240  
 tgcccgcgtta gcaagatata actatgcaat catgcaacaa agctgcctaa taacatttca 300  
 10 tttattacag gactaaaagt tcattattgt ttgtaaagga tgaattcata acctctgcag 360  
 agttatagtt catacacagt tgatttccat ttataaaggc agaaagtcct tgttttctct 420  
 aaatgtcaag ctttgactga aaactcccgt ttttccagtc actggagtggt gtgcgtatga 480  
 aagaaaatct ttagcaatta gatgggagag aagggaata gtacttgaaa tgtaggccct 540  
 cacctcccca tgacatcctc catgagcctc ctgatgtagt g

15 <210> 3  
 <211> 516  
 <212> DNA  
 <213> Human

&lt;400&gt; 3

25 tagagatggt ggttgatgac ccccgggatc tggagcagat gaatgaagag tctctggaag 60  
 tcagcccaga catgtgcac tacatcacag aggacatgct catgtcgagg aacctgaatg 120  
 gacactctgg gttgattgtg aaagaaattg ggtcttccac ctcgagctct tcagaaacag 180  
 ttgttaagct tcgtggccag agtactgatt ctcttccaca gactatatgt cggaaaccaa 240  
 agacctccac tgatcgacac agcttgagcc tcgatgacat cagactttac cagaaagact 300  
 tcctgagcat tgagggtctg tgtcaggaca ctgctcagag ttacaccttt ggatgtggcc 360  
 atgaactgga tgaggaaaggc ctctattgca acagttgctt ggcccagcag tgcataca 420  
 30 tccaagatgc ttttccagtc aaaagaacca gcaataactt ttctctggat ctactcatg 480  
 atgaagttcc agagtttgtt gtgtaaagtc cgtctg

<210> 4  
 <211> 1099  
 <212> DNA  
 <213> Human

&lt;400&gt; 4

40 cccacaacac agggggccctg aaacacgcca gcctctcctc tgtggtcagc ttggcccagt 60  
 cctgctcact ggatcacagc ccattgtagg tggggcatgg tggggatcag ggcccctggc 120  
 ccacggggag gtagaagaag acctggtccg tgtaagggtc tgagaagggt ccctgggtcg 180  
 ggggtgcegtc ttggccttgc cgtgccctca tccccgggt gaggcagcga cacagcaggt 240  
 gcaccaactc cagcaggtta agcaccaggg agatgagtc aaccaccaac atgaagatga 300  
 45 tgaagatggt cttctccgtg gggcgagaga caaagcagtc cagcaggtag gggcaggggtg 360  
 ctgctgggca cacaacacg ggctccatgg tccagccgta caggcgccac tggccataga 420  
 ggaagcctgc ctctagcaca ctcttgca gacactggc gacatagggt cccatcagtg 480  
 ctccgcggat gcgcaggcga ccatcttctg ccaccgagat cttggccatc tgacgtctta 540  
 cggccgcccag cggccgctcc acctgtgggt ccttggccgg cagtggccgc agctccccct 600  
 50 ccttctgccc cagccgctct tctcgccgag acaggtaaat gacatggccc aggtagacca 660  
 ggggtgggtgt gctgacgaag aggaactgca gcaccagta gcggatgtgg gagatgggga 720  
 aggcctgggtc ataggcagc ttggtgcagc ctggctgggc cgtgttacac tcgaaatctg 780  
 actgctcgtc accccacact gactcgccgg ccaggcccag gatgaggatg cggaagatga 840  
 agagcaccgt cagccagatc ttacccaacca cggtcgagtg ctctggacc tggccagca 900  
 55 acttctccac gaagccccag tcacccatgg ctccccggcc tccgtcgcca aggagacaga 960  
 gcacgtcagt gtgtcagcat ggcatccttc tcgttcgccc agcaacaagc ctgcagggag 1020  
 gtctgccacg cccgttctac cgctgcctg ccgggcggcc caggtggagg tggggacgat 1080  
 ggccggagtg acgcccgcg

60 <210> 5  
 <211> 1015  
 <212> DNA  
 <213> Human

&lt;400&gt; 5

65 gaggataggg agcctgggggt caggagtgtg ggagacacag cgagactctg tctccaaaaa 60

	aaaaagtgct	ttttgaaaat	gttgagggtg	aaatgatggg	aaccaacatt	ctttggattt	120
	agtggggagc	ataatagcaa	acacccccct	ggttcgcaca	tgtacaggaa	tgggacccag	180
	ttggggcaca	gcatggaact	tccccgccct	ggaatgtgtg	gtgcaaaagt	gggccagggc	240
5	ccagacccaa	gaggagagg	tggtccgcag	acaccccg	atgtcagcat	ccccgcacct	300
	gccttctggc	ggcacctccc	gggtgctgtg	ttgagtcagc	aggcatgggg	tgagagcctg	360
	gtatatgtcg	ggaacagggt	gcaggggcca	agcgttcctc	cttcagcctt	gacttggggc	420
	atgcaccccc	tctcccccaa	acacaaacaa	gcacttctcc	agtatggtgc	caggacaggt	480
	gtcccttcag	tcctctggtt	atgacctcaa	gtcctacttg	ggccctgcag	cccagcctgt	540
10	gttgtaacct	ctgcgtcctc	aagaccacac	ctggaagatt	cttcttccct	ttgaaggaga	600
	atcatcattg	ttgctttatc	acttctaaga	cattttgtac	ggcacggaca	agttaaacag	660
	aatgtgcttc	cctccctggg	gtctcacacg	ctcccacgag	aatgccacag	gggccgtgca	720
	ctgggcaggc	ttctctgtag	aaccccgagg	gcttcggccc	agaccacagc	gtcttgccct	780
	gagcctagag	cagggaggtc	cgaacttctg	cattcacaga	ccacctccac	aattgttata	840
	accaaaggcc	tcctgttctg	ttattttact	taaatcaaca	tgctattttg	ttttcactca	900
15	cttctgactt	tagcctcgtg	ctgagccgtg	tatccatgca	gtcatgttca	cggtgtagtt	960
	acgtttttct	tcttacacat	gaaaataaat	gcataagtgt	tagaagaaaa	aaaaa	
	<210> 6						
	<211> 2313						
20	<212> DNA						
	<213> Human						
	<400> 6						
25	ccagagcagg	cctgggtggg	agcagggagc	gtgcaccgga	cggcgggagc	gagcaaatgg	60
	gtctggccat	ggagcacgga	gggtccctacg	ctcggggcgg	gggcagctct	cggggctgct	120
	ggtattacct	gcgctacttc	ttcctcttcg	tctccctcat	ccaattcctc	atcatcctgg	180
	ggctcgtgct	cttcattggtc	tatggcaacg	tgcagctgag	cacagagtc	aacctgcagg	240
	ccaccgagcg	ccgagccgag	ggcctataca	gtcagctcct	agggctcacg	gcctcccagt	300
30	ccaacttgac	caaggagctc	aacttcacca	cccgcgccaa	ggatgccatc	atgcagatgt	360
	ggctgaatgc	tcgccgcgac	ctggaccgca	tcaatgccag	cttcgccag	tgccagggtg	420
	accgggtcat	ctacacgaac	aatcagaggt	acatggctgc	catcatcttg	agtgagaagc	480
	aatgcagaga	tcaattcaag	gacatgaaca	agagctgcga	tgcttgcctc	ttcatgctga	540
	atcagaaggt	gaagacgctg	gaggtggaga	tagccaagga	gaagaccatt	tgactaagg	600
35	ataaggaaag	cgtgctgctg	aacaaacgcg	tggcggagga	acagctgggt	gaatgcgtga	660
	aaacccggga	gctgcagcac	caagagcgcc	actggccaag	gagcaactgc	aaaaggtgca	720
	agccctctgc	ctgcccttgg	acaaggacaa	gtttgagatg	gaccttcgta	acctgtggag	780
	ggactccatt	atcccacgca	gcctggacaa	cctgggttac	aacctctacc	atccccctgg	840
	ctcgggaattg	gcctccatcc	gcagagcctg	cgaccacatg	cccagcctca	tgagctccaa	900
40	ggtggaggag	ctggcccggg	gcctccgggc	ggatategaa	cgcgtggccc	gcgagaactc	960
	agaccctcaa	cgccagaagc	tggaagccca	gcagggcctg	cgggccagtc	aggaggcgaa	1020
	acagaaggtg	gagaaggagg	ctcaggcccg	ggaggccaag	ctccaagctg	aatgctccc	1080
	gcagaccag	ctagcgtg	aggagaaggc	ggtgctgcgg	aaggaacgag	acaacctggc	1140
	caaggagctg	gaagagaaga	agagggaggc	ggagcagctc	aggatggagc	tgcccatcag	1200
45	aaactcagcc	ctggacacct	gcataaagac	caagtgcgag	ccgatgatgc	cagtgtcaag	1260
	gcccattggc	cctgtcccca	accccagcc	catcgaccca	gctagcctgg	aggagttaa	1320
	gaggaagatc	ctggagtccc	agaggccccc	tgcaggcatc	cctgtagccc	catccagtgg	1380
	ctgaggaggc	tccaggcctg	aggaccaagg	gatggcccga	ctcggcggtt	tgccgaggat	1440
50	gcagggatat	gctcacagcg	cccagacaaa	ccccctccc	ccgcccccaa	ccaccaggg	1500
	ccaccatcag	acaactccct	gcattgcaaac	ccctagtacc	ctctcacacc	cgaccccgcg	1560
	cctcacgac	cctcaccag	agcacagggc	cgccggagatg	acgtcacgca	agcaacggcg	1620
	ctgacgtcac	atatcacctg	ggtgatggcg	tcacgtggcc	atgtagacgt	cacgaagaga	1680
	tatagcgatg	gcgtcgtgca	gatgcagcac	gtcgcacaca	gacatgggga	acttggcatg	1740
	acgtcacacc	gagatgcagc	aacgacgtca	cgggccatgt	cgacgtcaca	catattaatg	1800
55	tcacacagac	gcggcgatgg	catcacacag	acggtgatga	tgtcacacac	agacacagtg	1860
	acaacacaca	ccatgacaac	gacacctata	gatattggcac	caacatcaca	tgacagcatg	1920
	ccctttcaca	cacactttct	acccaattct	cacctagtgt	cacgttcccc	cgaccctggc	1980
	acacgggcca	aggtacccac	aggatcccat	ccccctccgc	acagccctgg	gccccagcac	2040
	ctcccctcct	ccagcttctc	ggcctccag	ccacttctc	acccccagtg	cctggacccg	2100
60	gaggtgagaa	caggaagcca	ttcacctccg	ctccttgagc	gtgagtgttt	ccaggacccc	2160
	ctcggggccc	tgagccgggg	gtgaggtgca	cctgttgctg	ggaggggagc	cactccttct	2220
	cccccaacte	ccagccctgc	ctgtggcccg	ttgaaatgtt	ggtggcactt	aataaatatt	2280
	agtaaactct	taaaaaaaaa	aaaaaaaaaa	aaa			
65	<210> 7						
	<211> 389						



<212> DNA  
<213> Human

<400> 7

5

gccaaaaaga tggcttcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60  
gccactggat tcatgtctag aaaagatagg ataatttctg taaagaaatg aagaccttgc 120  
tattctaaaa tcagatccct acagatccag atttcaggaa acaaatacat aggggactaa 180  
ctttcttgt tcagattagt ttttctcctt tgcacccagc tatataatat gaggaagtat 240  
10 tgacttttta aaagtgtttt agttttccat ttctttgata tgaaaagtaa tatttcggga 300  
gaacctgag ctattaataa tctatgtggc tagtgcgtat atattggtct gaatttggtc 360  
tccttttgtg gtgtccagtg ggtaacatc

<210> 8  
<211> 157  
<212> DNA  
<213> Human

<400> 8

20

tgctttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggttttgtag 60  
gaagcaggaa gcaagccac tcaaactgta aatttggcat gagggatcca gtaactttct 120  
cctcaatctg tgaactatat gtgagtttga tattttg

<210> 9  
<211> 561  
<212> DNA  
<213> Human

<400> 9

30

aatagtcaaa acataaacia aagctaatta actggcactg ttgtcacctg agactaagtg 60  
gatgttgttg gctgacatac aggtcagcc agcagagaaa gaattctgaa ttccccttgc 120  
35 tgaactgaac tattctgtta catatgggtg acaaactctgt gtgttatttc ttttctacct 180  
accatattta aatttatgag tatcaaccga ggacatagtc aaaccttcca tgatgaacat 240  
tcctgatttt ttgacctgatt aatctctgtt gagctctact tgtggtcatt caagatttta 300  
tgatgttgaa aggaaaagtg aatatgacct ttaaaaaattg tattttgggt gatgatagtc 360  
tcaccactat aaaactgtca attattgcct aatgttaaag atatccatca ttgtgattaa 420  
ttaaacttat aatgagtatt cttaatggag aattcttaat ggatggatta tcccctgac 480  
40 ttttctttaa aatttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540  
ctgcccacat ttctaggaaa a

<210> 10  
<211> 1508  
<212> DNA  
<213> Human

<400> 10

50

cacaaacacg agagactcca cggctctgcct gagcaccgcc agcctcctag gctccagcac 60  
tcgcaggtcc attcttctgc acgagcctct ctgtccagat ccataagcac ggtcagctca 120  
gggtcgcgga gcagtagag gacaagtacc agcagcagct cctctgaaca gagactgcta 180  
ggatcatcct tctctccgg gcctgttgct gatggcataa tccgggtgca acccaaatct 240  
gagctcaagc caggtgagct taagccactg agcaaggaag atttgggcct gcacgcctac 300  
55 aggtgtgagg actgtggcaa gtgcaaagt aaggagtgc cctacccaag gcctctgcca 360  
tcagactgga tctgcgaca gcagtgcctt tgctcggccc agaactgat tgactatggg 420  
acttgtgtat cgtgtgtgaa aggtctcttc tatcactgtt ctaatgatga tgaggacaac 480  
tgtgtgaca acccatgttc ttgcagccag tctcactgtt gtacacgatg gtcagccatg 540  
gggtgcatgt cctcttttt gccttgttta tgggtgttacc ttccagccaa ggggtgcctt 600  
60 aaattgtgcc aggggtgtta tgaccgggtt aacaggcctg gttgccgctg taaaaactca 660  
aacacagttt gctgcaaagt tcccactgtc ccccttagga actttgaaaa accaacaatg 720  
catcattaat caggaaatatt acagtaatga ggattttttc tttctttttt taatacacat 780  
atgcaaccaa ctaaacagtt ataactcttg cactgttaat agaaagttgg gatagctttt 840  
gctgtttgag gtgaaatgct ttttgtccat gtgccgtttt aactgatatg cttgttagaa 900  
65 ctcagctaata ggagctcaaa gtatgagata cagaacttgg tgacctatgt attgcataag 960  
ctaaagcaac acagacactc ctaggcaaa tttttgtttg tgaatagtag ttgcaaaact 1020

5 tgtaaattag cagatgactt ttttccattg ttttctccag agagaatgtg ctatatTTTT 1080  
 gtatatacaa taatatTTTgc aactgtgaaa aacaagtggg gccatactac atggcacaga 1140  
 cacaaaatat tatactaata tgggtgtacat tcggaagaat gtgaatcaat cagtatgttt 1200  
 ttagattgta ttttgcctta cagaaagcct ttattgtaag actctgattt ccctttgggac 1260  
 5 ttcatgtata ttgtacagtt acagtataaat tcaaccttta ttttctaatt ttttcaacat 1320  
 attgttttagt gtaaagaata tttatttgaa gttttattat tttataaaaa agaataTTTta 1380  
 ttttaagagg catcttataa attttgcccc ttttatgagg atgtgatagt tgctgcaaat 1440  
 gaggggttac agatgcatat gtccaatata aaatagaaaa tatattaacg tttgaaatta 1500  
 aaaaaaaa  
 10 <210> 11  
 <211> 389  
 <212> DNA  
 <213> Human  
 15 <400> 11  
 20 gggcaggtga tcagggcaca catttcccgt ccattgagac agtagcattc ccggcaccca 60  
 tcgtgccagc tctcctcatt tttatgatga tgaccatcca cgggtgagaca agtgccccgac 120  
 aggatgggtg gccagctga agcacaggcc gctctgcact tgcagataag acagccgtga 180  
 ctgtcctgct ggaaacccaa tgggcagatc ttactgcatg agagctctgg acatttctta 240  
 cagcgacaga tgtcacagcc gtgcttattc ttcagcaatc caagtggaca atacttgtca 300  
 cagattatgg gtctgcactt cttgggcctt gggcggcact cacagatctc acagtttttg 360  
 25 acctcggccg cgaccacgct ggtaccga  
 <210> 12  
 <211> 981  
 <212> DNA  
 <213> Human  
 30 <400> 12  
 35 tttttttttt ttggattgca aaaattttatt aaaattggag acactgtttt aatcttcttg 60  
 tgccatgaga ctccatcagg cagtctacaa agaccactgg gaggtgagg atcacttgag 120  
 cccagaagtt tgaggctgta gtaagcttca aaggccactg cactctagct tgggtgaggc 180  
 aagacccttt caagcagtaa gctgcatgct tgcttgttgt gggtcattaaa aaccctagtt 240  
 taggataaca acatattaat cagggcaaaa taaaaatgtg tgatgcttgt tagtagagta 300  
 acctcagaat caaaatggaa cggttttaca gtgatcatat tatatttcat ttggcagaat 360  
 40 cattacatca ttggttacac tgaaaatcat cacatgtacc aaaagctgac tcacctagtt 420  
 taggataaca ggtctgcctg tttgaagatg aaaaataata cccatttaa atttgcccta 480  
 ctcaatttcc ttctcagtca cattttaact tttaaacagc taactactcc catctacaga 540  
 ttaagggtgta tatgccacca aaaccttttg ccaccttaaa aatttccttc aaagtttaaa 600  
 ctaatgcctg catttcttca atcatgaatt ctgagtcctt tgcttcttta aaacttgctc 660  
 45 cacacagtgat agtcaagccg actctccata cccaagcaag tcatccatgg ataaaaacgt 720  
 taccaggagc agaaccatta agctgggtcca ggcaagttgg actccaccat ttcaacttcc 780  
 agctttctgt ctaatgcctg tgtgccaatg gcttgagtta ggcttgctct ttaggacttc 840  
 agtagctatt ctcatccttc cttggggaca caactgtcca taaggtgcta tccagagcca 900  
 cactgcatct gcacccagca ccatacctca caggagtcca ctcccacgag ccgcctgtat 960  
 50 ataagagttc ttttgatgac g  
 <210> 13  
 <211> 401  
 <212> DNA  
 <213> Human  
 55 <400> 13  
 60 ataactacag cttcagcaga caactaaaga gactgcatta aggtgatttc tctggtata 60  
 aagagagccc ggccgcagag catgtgactg ctgggacctc tgggataggc aacttgccc 120  
 tctctcccc agagcgaccc cccgggcagg tcggggccca aggaatgacc cagcaactgc 180  
 tccctaccca gcacactctc tttactgcca cctgcaatta tgctgtgaag atgactgggt 240  
 gtggtcatca cgattcagag aatcaagat ctatgaccat tttaggcaaa gagagaaact 300  
 tggagaattg ctgaggacta ctgaaccttg ttttgctttt ttaaaaaata ctaaatcctc 360  
 65 acttcagcat atttagttgt cattaaaatt aagctgatat t  
 <210> 14

<211> 1002  
 <212> DNA  
 <213> Human

5 <400> 14

gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60  
 acagttgtgg agaacagggt gagtagagca acaacaacaa aagcttatgc agtcaccttc 120  
 10 tttgaaaatg ttaaatataca gtcctattct ctttgtccag ctgggttttag ctagaggtag 180  
 ccaattactt ctcttaaggt ccatggcatt cgccaggatt ctataaaagc caagttaact 240  
 gaagtaataa tctggggccc atcgaccccc cactaagtac tttgtcacca tgttgatatct 300  
 taaaagtcatt ttttactgtt ttgactcaga atttgggact tcagagtcaa acttcattgc 360  
 ttactccaaa cccagtttaa ttccccactt ttttaagtag gcttagcttt gagtgatttt 420  
 15 tggctataac cgaaatgtaa atccaccttc agacatttcc ccaagataac tgccaaagag 480  
 tactgaaaac aatggtgcca tatgctccaa gtagggagcct tgatatctct gcaaaataga 600  
 tttttgagga ggacaatgat catttattat gtagggagcct tgcataatgc attttttcat tcatacatte 720  
 attaatacag ctcaaagtga gtagtaacca agcttttctg cccaggaagt aacaaacatc 660  
 actacgaaca tgagagtaca agaggaaact ttcataatgc attttttcat tcatacatte 720  
 20 attcaataaa cattagccaa gctaattgtc caagccactg tgccagggtat taacaatata 780  
 acaacaataa aagacacagt ccttcctctc aaggtgttca gtctagtagg gaagatgatt 840  
 attcattaaa atttttggtg catcagaatc atgaggagct tgtcaaaaat gtaaattcct 900  
 gcctatgttc tcagatattc tggtaggttc agggagtggga acccaaaatc aattctttta 960  
 acaaacacta aaggtgatcc taacacaggc ggtgtgagga cc

25 <210> 15  
 <211> 280  
 <212> DNA  
 <213> Human

30 <400> 15

cgaggtgggc caccctgtgc tggctctgaga tttttaaatg aggattacat tatectatct 60  
 ataattattcc tatttctaate tattgtattc ttacaattaa atgtatcaaa taattcttaa 120  
 35 aacattattt agaacaacac tgcctaatac cttataagac taaaaaaatc accaagatga 180  
 aactgtatta tgactctcaa tatttaaaca ttttaaaaaa tgttagtggt tgtaaagcac 240  
 caatcttaac tatttcacct gcccgggcgg cgcctcgagg

40 <210> 16  
 <211> 2041  
 <212> DNA  
 <213> Human

<400> 16

45 cccccgcag aactcccccc tgggaatagga tttttaaaac ccttgacaat tagaaatcct 60  
 atagagggtta gcattttttta ggtaaaaata tgggtgcccc tacagggatc atgcaacttc 120  
 cttaaaacca attcagcaca tatgtataaa gaaccctttt taaaaacatt tgtacttgaa 180  
 atacagacac agtgatgctg aagacactaa acaaaaactg aaaagtacta taccttgata 240  
 50 aattttgtta ttgccttctt tagagacttt ataactctta gttgattttc aaggacttga 300  
 atttaataat ggggtaatta cacaagacgt aaaggatttt ttaaaaacaa gtattttttt 360  
 ttacctctag catcaattct tttataaaga atgctaaata aattacattt tttgttcagt 420  
 aaaactgaag atagaccatt taaatgcttc taccaaaatt aacgcagctt aattagggac 480  
 caggtacata ttttcttctg aacattttttg gtcaagcatg tctaaccata aaagcaaatg 540  
 55 gaattttaag aggtagattt tttttccatg atgcattttg ttaataaatg tgtcaagaaa 600  
 ataaaaacaa gcactgagtg tgttctcttg aagtataagg gtctaataaa aaataaaaga 660  
 tagatatattg ttatagcttg acatttttaac agtcatagta ttagacggtt cgtgaccagt 720  
 gcatttttga ctctctcagg atcaaaaatac agtctcgcca actgtattaa atcctcctcc 780  
 accccctcca ccagttggtc cacagcttcc tgggtgggtcg ttgtcatcaa atccattggg 840  
 60 ccgaaatgaa catgaagcag atgcagcttg gagggcccg gctcgagcat tcaactcttg 900  
 ttctgtgaaa tatagtttat tgtcttttgt tatagcatcc ataagttctt tctgtagagg 960  
 tgggtctcca tttatccaga gtccactggt tgggttatta ccacttaaac cattagtact 1020  
 atgctgtttt ttatacaaaa gcacataaag tgtgtccttt ggaaacctgc tctgaatttt 1080  
 ctggactgac tgaaatgaag taaatgtcac tctactgtca ttaaataaaa acccttctt 1140  
 65 ttgacatttc cttattttcc aaatcctggt caaaaactgc actgggacta tctctcccta 1200  
 gtaaatgact ctgggaggat gctaattgcca gagcctcaga ctggtggtac atctgatatg 1260  
 aagagtctgt acttgtgata tttctggcat aagaatagta atgcccactt tcagaggata 1320

5 taccagagtg aaccacaacg gaacttaata gatagggcac caattttgtg caggaagctt 1380  
 catcagtcctc tgaaggcttt aatttttttag caagggttctc actaagatca gtgaagtcaa 1440  
 catctacaga ccaactttct gacaatgaag agaaagaagt aattcttcta actggcaact 1500  
 ccaaaaccag tggccagtga tacattgtct aaaattttcc ttctcacatg atactttctga 1560  
 tcatatgaaa atctcaggag agtaagaata aggtattcag gttcctccgt gatttgcata 1620  
 gttttctcag cattttgcag agaggcacag ttttcacaat aatattgggt atcaccagta 1680  
 agaattctctg gagecccaaaa aataatttag taagtcagtt actgaagggtg tggtttcacc 1740  
 tcccggtttc tgaggtagat ctttattaac aagaatcttg ttagattcgt tagggacaga 1800  
 10 agtggtttca gaacagtaaa actcattagg aggactgcct atgggttttt cattcacaag 1860  
 tgagtcacag atgaaggcag ctgttggttg attataaact actggctctt ctgaaggacc 1920  
 gggtagacag gcttgcatga gaccaccatc ttgtatactg ggtgatgatg ctggatcttg 1980  
 gacagacatg ttttccaaag aagaggaagc acaaaacgca agcgaaagat ctgtaaaggc 2040  
 t

15 <210> 17  
 <211> 235  
 <212> DNA  
 <213> Human

20 <400> 17

25 cgccccgggc aggtgtcagg ggttccaaac cagcctgggg aaacacagcg tagaccctc 60  
 acctctacaa ataaaaaatt aaaaaattag ccagggtgtg cagcgaacaa ctgtagtctc 120  
 agatactcag gagactgagc tggaaaggat cacttgagcc caagaagttc aaggttacag 180  
 tgggccacga tcatgtcatt acactccagc ttgggtgaca aaatgagact gtcta

<210> 18  
 <211> 2732  
 <212> DNA  
 30 <213> Human

<400> 18

35 gtgtggagtt tcagctgcta ttgactataa gagctatgga acagaaaaag cttgctggct 60  
 tcatgttgat aactacttta tatggagctt cattggacct gttaccttca ttattctgct 120  
 aaatattatc ttcttgggtga tcacattgtg caaaatggtg aagcattcaa acactttgaa 180  
 accagattct agcagggttg aaaacattaa gtcttgggtg cttggcgctt tcgctcttct 240  
 gtgtcttctt ggcctcacct ggtccttttg gttgcttttt attaatgagg agactattgt 300  
 gatggcatat ctcttcacta tatttaatgc tttccaggga gtgttcattt tcatctttca 360  
 40 ctgtgctctc caaaagaaaag tacgaaaaga atatggcaag tgcttcagac actcatactg 420  
 ctgtggaggc ctcccaactg agagtcccca agttcagtg aaggcatcaa ccaccagaac 480  
 cagtgtctgc tattcctctg gcacacagag tcgtataaga agaattgtga atgatactgt 540  
 gagaaaacaa tcagaatctt cttttatctc aggtgacatc aatagcactt caacacttaa 600  
 tcaagggtggc ataaatctta atatatattt acaggactga catcacatgg tctgagagcc 660  
 45 catcttcaag atttatatca ttttagaggac attcactgaa caatgccagg gatacaagt 720  
 ccatggatac tctaccgcta aatggtaatt ttaacaacag ctactcgtg cacaaggggtg 780  
 actataatga cagcgtgcaa gttgtggact gtggactaag tctgaatgat actgctttt 840  
 agaaaatgat catttcagaa ttagtgcaca acaacttacg gggcagcagc aagactcaca 900  
 acctcgagct cacgctacca gtcaaacctg tgattggagg tagcagcagt gaagatgatg 960  
 50 ctattgtggc agatgcttca tctttaatgc acagcgacaa cccagggtcg gagctccatc 1020  
 acaaagaact cgaggcacca cttattcctc agcggactca ctcccttctg taccaacccc 1080  
 agaagaaagt gaagtccgag ggaactgaca gctatgtctc ccaactgaca gcagaggctg 1140  
 aagatcacct acagtcccc aacagagact ctctttatac aagcatgccc aatcttagag 1200  
 actctcccta tccggagagc agccctgaca tggagaaga cctctctccc tccaggagga 1260  
 55 gtgagaatga ggacatttac tataaaagca tgccaaatct tggagctggc catcagcttc 1320  
 agatgtgcta ccagatcagc aggggcaata gtgatgggtt tataatcccc attaacaaag 1380  
 aaggggtgat tccagaagga gatgttagag aaggacaaat gcagctgggt acaagtcctt 1440  
 aatcatacag ctaaggaatt ccaagggcca catgagagta ttaataaata aagacaccat 1500  
 tggcctgacg cagctccctc aaactctgct tgaagagatg actcttgacc tgtggttctc 1560  
 60 tgggtgtaaaa aagatgactg aaccttgacg ttctgtgaat tttataaaa catacaaaaa 1620  
 ctttgatat acacagagta tactaaagt aattatttgt tacaagaaa agagatgcca 1680  
 gccagggtatt ttaagattct gctgctgttt agagaatttg tgaacaagc aaaacaaaac 1740  
 tttccagcca ttttactgca gcagtctgtg aactaaattt gtaaatatgg ctgcaccatt 1800  
 tttgtaggcc tgcattgtat tatatacaag acgtaggctt taaaatcctg tgggacaaat 1860  
 65 ttactgtacc ttactattcc tgacaagact tggaaaagca ggagagatat tctgcatcag 1920  
 tttgcagttc actgcaaatc ttttacatta aggcaaaagt tgaaaacatg ctttaaccat 1980

	agcaatcaag	ccacaggcct	tatttcatat	gtttcctcaa	ctgtacaatg	aactattctc	2040
	atgaaaaatg	gctaaagaaa	ttatatattt	ttctattgct	agggtaaaa	aaatacattt	2100
	gtgtccaact	gaaatataat	tgctattaaa	ataattttta	agagtgaaga	aaatattgtg	2160
5	aaaagctctt	ggttgcacat	gttatgaaat	gttttttctt	acactttgtc	atggtaagtt	2220
	ctactcattt	tcacttcttt	tccactgtat	acagtgttct	gctttgacaa	agttagtctt	2280
	tattactttac	atttaaattt	cttattgcca	aaagaacgtg	ttttatgggg	agaacaaaac	2340
	tctttgaagc	cagttatgtc	atgccttgca	caaaagtgat	gaaatctaga	aaagattgtg	2400
	gtgcacccct	gtttattctt	gaacagaggg	caaagagggc	actgggcact	tctcacaac	2460
10	tttctagtga	acaaaagggtg	cctattcttt	tttaaaaaaa	taaaataaaa	cataaatatt	2520
	actcttccat	attccttctg	cctatatatta	gtaatttaatt	tattttatga	taaagttcta	2580
	atgaaatgta	aattgtttca	gcaaaattct	gctttttttt	catccctttg	tgtaaacctg	2640
	ttaataatga	gcccatcact	aatatccagt	gtaaagttta	acacggtttg	acagtaaata	2700
	aatgtgaatt	ttttcaagtt	aaaaaaaaaa	aa			
15	<210> 19						
	<211> 276						
	<212> DNA						
	<213> Human						
20	<400> 19						
	ctccctaaat	gatttttaaaa	taaattggat	aaacatatga	tataaagtgg	gtacttttaga	60
	aaccgccttt	gcatattttt	tatgtacaaa	tctttgtata	caattccgat	gttccctata	120
25	tattccctat	atagcaaac	aaaaccagga	cctcccaact	gcatgcctca	agtcctctgt	180
	gagcactctg	gcaactggat	ggcctactt	gctttctgac	aaaatagctg	gaaaggagga	240
	gggaccaatt	aaatacctcg	gccgcgacca	cgctgg			
	<210> 20						
	<211> 2361						
30	<212> DNA						
	<213> Human						
	<400> 20						
35	attgtaccag	ccttgatgaa	cgtagggcct	gcttcgcttt	tgaggggccat	aagctcattg	60
	cccactgggt	tagaggctac	cttatcattg	tctcccgtga	ccggaagggt	tctcccaagt	120
	cagagtttac	cagcagggat	tcacagagct	ccgacaagca	gattctaaac	atctatgacc	180
	tgtgcaacaa	gttcatagcc	tatagcaccg	tctttgagga	tgtagtggtg	gtgcttgctg	240
40	agtggggctc	cctgtacgtg	ctgacgcggg	atgggcgggt	ccacgcactg	caggagaagg	300
	acacacagac	caaactggag	atgctgttta	agaagaacct	atttgagatg	gcgattaacc	360
	ttgccaagag	ccagcatctg	gacagtgatg	ggctggccca	gattttcatg	cagtatggag	420
	accatctcta	cagcaagggc	aaccacgatg	gggctgtcca	gcaatataat	cgaaccattg	480
	gaaagtgtga	gccatcctac	gtgatccgca	agtttctgga	tgcccagcgc	attcacaacc	540
45	tgactgecta	cctgcagacc	ctgcaccgac	aatccctggc	caatgccgac	cataccaccc	600
	tgctcctcaa	ctgtataacc	aagctcaagg	acagctcgaa	gctggaggag	ttcatcaaga	660
	aaaagagtga	gagtgaagtc	tgtagacagc	catcaagggt	ctccggcagg	720	
	ctggctacta	ctcccatgcc	ctgtatctgg	cgagagaacca	tgacatcat	gagtgttacc	780
	tgaagatcca	gctagaagac	attaagaatt	atcaggaagc	ccttcgatac	atcggcaagc	840
50	tgcttttga	gcaggcagag	agcaacatga	agcgctacgg	caagatcctc	atgcaccaca	900
	taccagagca	gacaactcag	ttgctgaagg	gactttgtac	tgattatcgg	cccagcctcg	960
	aaggccgcag	cgataggagg	gccccaggct	gcaggggcaa	ctctgaggag	ttcatcccca	1020
	tctttgccaa	taaccgcgca	gagctgaaag	ccttcctaga	gcacatgagt	gaagtgcagc	1080
	cagactcacc	ccaggggatc	tacgacacac	tccttgagct	gcgactgcag	aactgggccc	1140
55	acgagaagga	tccacaggct	aaagagaagc	ttcacgcaga	ggccatttcc	ctgctgaaga	1200
	gtggctcgctt	ctgcgacgtc	tttgacaagg	ccctggtect	gtgccagatg	cagcacttcc	1260
	aggatggtgt	cctttacctt	tatgagcagg	ggaagctgtt	ccagcagatc	atgcactacc	1320
	acatgcagca	cgagcagtac	cggcaggtca	tcagcgtgtg	tgagcgccat	ggggagcagg	1380
	acccctcctt	gtgggagcag	gccctcagct	acttcgctcg	caaggaggag	gactgcaagg	1440
60	agtatgtggc	agctgtcctc	aagcatatcg	agaacaagaa	cctcatgcca	cctcttctag	1500
	tggtgcagac	cctggcccac	aactccacag	ccacactctc	cgatcatcag	gactacctgg	1560
	tccaaaaact	acagaaacag	agccagcaga	ttgcacagga	tgagctgcgg	gtgcggcggt	1620
	accgagagga	gaccaccctg	atccgccagg	agatccaaga	gctcaaggcc	agtcctaaga	1680
	ttttccaaaa	gaccaagtgc	agcatctgta	acagtgcctt	ggagttgccc	tcagtccact	1740
65	tcctgtgtgg	ccactccttc	caccaacact	gctttgagag	ttactcggaa	agtgtatgctg	1800
	actgccccac	ctgcctccct	gaaaaccgga	aggtcatgga	tatgatccgg	gccaggaac	1860
	agaaacgaga	tctccatgat	caattccagc	atcagctcaa	gtgctccaat	gacagctttt	1920

	ctgtgattgc	tgactacttt	ggcagagggtg	ttttcaacaa	attgactctg	ctgaccgacc	1980
	ctcccacagc	cagactgacc	tccagcctgg	aggctgggct	gcaacgcgac	ctactcatgc	2040
	actccaggag	gggcacttaa	gcagcctgga	ggaagatgtg	ggcaacagtg	gaggaccaag	2100
5	agaacagaca	caatgggacc	tgggcgggcg	ttacacagaa	ggctggctga	catgcccagg	2160
	gctccactct	catctaattg	cacagccctc	acaagactaa	agcggaaactt	tttcttttcc	2220
	ctggccttcc	ttaattttta	gtcaagcttg	gcaatccctt	cctcttttaac	taggcagggtg	2280
	ttagaatcat	ttccagatta	atgggggggga	aggggaacct	caggcaaacc	tcctgaagtt	2340
	ttggaaaaaa	aagctggttt	c				
10	<210> 21						
	<211> 179						
	<212> DNA						
	<213> Human						
15	<400> 21						
	agggtgtaga	tgctcttgaa	aaagaaactg	catctaagct	gtcagaaatg	gattcttttta	60
	acaatcaact	aaaggaaactg	agagaaacct	acaacacaca	gcagttagcc	cttgaacagc	120
20	tttataagat	caacgtgaca	agttgaagga	aattgaaagg	aaaaaattag	aactaatgc	
	<210> 22						
	<211> 905						
	<212> DNA						
	<213> Human						
25	<400> 22						
	tttttttttt	ttctttaacc	gtgtgggtctt	tatttcagtg	ccagtgttac	agatacaaca	60
30	caaatgttcc	agttagaagg	aattcaaacy	gaatgccaa	gtccaagcca	ggctcaagaa	120
	ataaaaagg	aggtttgag	taatagataa	gatgactcca	atactcactc	ttcctaagg	180
	caaagggtact	tttgatacag	agtctgatct	ttgaaactgg	tgaactcctc	ttccacccat	240
	taccatagtt	caaacaggca	agttatgggc	ttaggagcac	tttaaaattt	gtggtgggaa	300
	tagggctcatt	aataactatg	aatatatctt	ttagaagggtg	accattttgc	actttaaagg	360
35	gaatcaattt	tgaaaatcat	ggagactatt	catgactaca	gctaaagaat	ggcgagaaag	420
	gggagctgga	agagccttgg	aagtttctat	tacaaataga	gcaccatata	cttcatgcca	480
	aattctcaaca	aaagctcttt	ttaactccat	ctgtccagtg	tttacaataa	aactcgcaag	540
	gtctgaccag	ttcttggtta	caaacataca	tgtgtgtgtc	tgtgtgtata	cagcaatgca	600
	cagaaaaagg	taccaggagc	ctaattgcctc	tttcaaacat	tgggggaacc	agtagaaaaa	660
40	ggcagggtct	cctaattgtcc	attattacat	ttccattccg	aatgccagat	gttaaaagt	720
	cctgaagatg	gtaaccagc	tagtgaggaa	taaatacccc	accttgccca	gtccacagag	780
	aaacaacagt	agaaagaagg	ggcaactctt	tgtgcagag	acaaagtgag	tgttttttcg	840
	ccatggattg	cagtcctctc	ctccagacca	gctgcttatt	tcctcagggg	cccaggggaat	900
	gttga						
45	<210> 23						
	<211> 2134						
	<212> DNA						
	<213> Human						
50	<400> 23						
	ggtctcttct	ttcttttttt	tttttccaaa	agtgttcttt	tatttctagt	aacatatatt	60
	gtataaatac	tctattttat	atgcacttcc	acaaaagcga	tataatttta	aagttttttt	120
55	cattagaaat	aaatgtataa	aaataaatat	gttattatag	gcattttatta	ctaactatag	180
	tccttcttgg	aaggaacacc	caaaccaata	cttataaagt	acatgtaatt	tatagtaaca	240
	tattttacta	tatacatatg	gaaaaaatca	tattctcaca	gaagagctga	acagacattc	300
	accaggatac	gactgtttga	ccagctgctg	gagatggacc	tgctaccctt	cagcagcctc	360
	cccaccacaa	gacaagtgat	ctcaatgtcc	ccaaacctgt	gggacctgt	tctacacacc	420
60	tcatttttgt	tccggcggtt	catcctcctt	gtgtgattgt	actgattttc	atgagacaca	480
	agttacttct	ttacatccat	attcccaaag	cagggttaca	tggtaggaaa	gaaaggaagt	540
	tggaggtaact	aagctcattg	tgctcctctt	agcttttacc	agcatcta	gcttctactgc	600
	tttttttcca	ttgtagactt	taatgcactt	gaataaatac	atggagttgt	tttttctctca	660
	aaatgaatta	cacaaataaa	gactgagatg	gtccaaaaaa	ggaaagagga	agccattttgc	720
65	gttattttcac	gttgctgagc	ctttctctca	tggtgaacaa	tctgaagttt	taattctcgg	780
	tagaaataat	gtataaacat	tctctgaaac	catagcagcc	ataaacagt	ctgggtcaaag	840
	atcctatttg	tactcctttc	tccccccatt	gttagtgagg	taaagtaaaa	caggtcttag	900

5 taaaatctca cttttctcct acttttcatt tcccaacccc catgatacta agtattttgat 960  
 aagtaccagg aaacaggggt tgtaatagtt ctaacttttt ttgacaattg ctttgttttt 1020  
 tctaaacttg taatagatgt aacaaaagaa ataataataa taatgcccggt ggctttatta 1080  
 tgctatatca ctgctcagag gtttaataatc ctactaact atcctatcaa atttgcaact 1140  
 10 ggcagtttac tctgatgatt caactccttt tctatctacc ccataatcc caccttactg 1200  
 atacacctca ctggttactg gcaagatacg ctggatccct ccagccttct tgctttccct 1260  
 gcaccagccc ttctcacttt tgctttgccc tcaaagctaa caccacttaa accacttaac 1320  
 tgcattctgc cattgtgcaa aagtctatga aatgtttagg tttcttttaa ggatcacagc 1380  
 tctcatgaga taacacccct ccatcatggg acagacactt caagcttctt tttttgtaac 1440  
 ctttcccaca ggtcttagaa catgatgacc actccccag ctgccactgg gggcagggat 1500  
 ggtctgcaca aggtctggtg ctggctggct tcaactcctt tgcacactcg gaagcaggct 1560  
 gtccattaat gtctcggcat tctaccagtc ttctctgcca acccaattca catgacttag 1620  
 aacattcgcc ccactcttca atgacccatg ctgaaaaagt ggggtagatga ttgaaagatt 1680  
 15 ctttcttctt ctttacgaag taggtgtatt taattttagg tcgaagggca ttgccacag 1740  
 taagaacctg gatggtcaa ggccttttga gagggctaaa gctgcgaatt ctttccaatg 1800  
 ccgcagagga gccgctgtac ctcaagacaa cacttttga cataatgtct tgctctaagg 1860  
 tggacaaagt gtagtcacca ttaagaatat atgtgccatc agcagctttg atggcaagaa 1920  
 agctgccatt gttcctggat cccctctggt tccgctggtt cacttcgatg ttggtggctc 1980  
 cagttggaat tgtgatgata tcatgatatc caggttttgc actagtaact gatcctgata 2040  
 20 tttttttaca agtagatcca ttccccgc aaacaccaca tttatcaaac ttctttttgg 2100  
 agtctatgat gcgatcacia ccagctttta caca

&lt;210&gt; 24

&lt;211&gt; 1626

25 &lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 24

30 ggacaatttc tagaatctat agtagtatca ggatatattt tgctttaaaa tatattttgg 60  
 ttattttgaa tacagacatt ggctccaaat ttcatctttt gcacaatagt atgacttttc 120  
 actagaactt ctcaacattt gggaaactttg caaatatgag catcatatgt gtttaaggctg 180  
 tatcatttaa tgctatgaga tacattgttt tctccctatg ccaaacaggt gaacaaacgt 240  
 35 agttgttttt tactgatact aaatgtttggc tacctgtgat tttatagtat gcacatgtca 300  
 gaaaaaggca agacaaatgg cctcttgtac tgaatacttc ggcaaaactta ttgggtcttc 360  
 attttctgac agacaggatt tgactcaata tttgtagagc ttgcgtagaa tggattacat 420  
 ggtagtgatg cactggtaga aatggttttt agttattgac tcagaattca tctcaggatg 480  
 aatcttttat gtctttttat tgtaagcata tctgaattta ctttataaag atggtttttag 540  
 40 aaagctttgt ctaaaaattt ggcctaggaa tggtaacttc attttcagtt gccaaaggggt 600  
 agaaaaataa tatgtgtgtt gttatgttta tgtaacata ttattaggta ctatctatga 660  
 atgtatttaa atatttttca tattctgtga caagcattta taatttgcaa caagtggagt 720  
 ccatttagcc cagtgggaaa gtcttggaaac tcaggttacc cttgaaggat atgctggcag 780  
 ccattctctt gatctgtgct taaactgtaa tttatagacc agctaaatcc ctaacttgga 840  
 45 tctggaatgc attagttatg ccttgtacca ttcccagaat ttcaggggca tcgtgggttt 900  
 ggtctagtga ttgaaaacac aagaacagag agatccagct gaaaaagagt gatcctcaat 960  
 atcctaacta actggtcctc aactcaagca gagtttcttc actctggcac tgtgatcatg 1020  
 aaacttagta gaggggattg tgtgtatttt atacaaattt aatacaatgt cttacattga 1080  
 taaaattctt aaagagcaaa actgcatttt atttctgcat ccacattcca atcatattag 1140  
 50 aactaagata tttatctatg aagatataaa tgggtgcagag agactttcat ctgtggattg 1200  
 cgttgtttct tagggttctt agcactgatg cctgcacaag catgtgatat gtgaaataaa 1260  
 atggattctt ctatagctaa atgagttccc tctggggaga gttctgggtac tgcaatcaca 1320  
 atgccagatg gtgtttatgg gctattttgtg taagtaagt gtaagatgct atgaagtaag 1380  
 tgtgtttgtt ttcactctat ggaaactctt gatgcatgtg cttttgtatg gaataaattt 1440  
 55 tggtgcaata tgatgtcatt caactttgca ttgaattgaa ttttggttgt atttatatgt 1500  
 attataacct tcacgcttct agttgcttca accattttat aaccattttt gtacatattt 1560  
 tacttgaaaa tatttttaaat ggaaatttaa ataaacattt gatagtttac ataataaaaa 1620  
 aaaaaa

&lt;210&gt; 25

60 &lt;211&gt; 1420

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 25

65 gttcagcatt gtttctgctt ctgaaactcg tatagtacac tggtttgtaa tcattatgtc 60

	ttctattgaa	tccttctctac	ttctcttctct	cttcaatgaa	agacacgaga	gacaagagcg	120
	acacaagctt	aagaaaaacg	agcaaggaag	agtatcttca	tatttctcat	tttctctgag	180
	ttggaacaa	aaacatgaag	gactccaact	agaagacaga	tatttacatt	taaatagatt	240
5	agtgggaaaa	ctttaagagt	ttccacatat	tagttttcat	tttttgagtc	aagagactgc	300
	tccttgtact	gggagacact	agtagtatat	gtttgtaatg	ttacttttaa	attatctttt	360
	tattttataa	ggcccataaa	tactgggttaa	actctgttaa	aagtgggcct	tctatcttgg	420
	atgggttcac	tgccatcagc	catgctgata	tattagaaat	ggcatcccta	tctacttact	480
	ttaatgctta	aaattataca	taaaatgctt	tatttagaaa	acctacatga	tacagtgggtg	540
10	tcagccttgc	catgtatcag	tttcaactga	aatttgagac	caattaaatt	tcaactgttt	600
	aggggtggaga	aagaggtact	ggaaaacatg	cagatgagga	tatcttttat	gtgcaacagt	660
	atcctttgca	tgggaggaga	gttactcttg	aaaggcagcg	agcttaagtg	gacaatgttt	720
	tgtatatagt	tgagaatttt	acgacacttt	taaaaattgt	gtaattgtta	aatgtccagt	780
	tttgctctgt	tttgcctgaa	gttttagtat	ttgttttcta	ggtagacctc	tgaaaaccaa	840
15	accagtacct	ggggagggtta	gatgtgtgtt	tcaggcttgg	agtgtatgag	tggttttgc	900
	tgtattttcc	tccagagatt	ttgaacttta	ataattgcgt	gtgtgttttt	ttttttttta	960
	gtggctttgt	tttttttct	caagtaaaat	tgtgaacata	tttcttttat	aggggcaggg	1020
	catgagttag	ggagactgaa	gagtattgta	gactgtacat	gtgccttctt	aatgtgttct	1080
	tcgacacatt	ttttttcagt	aacttgaaaa	ttcaaaaggg	acatttgggt	aggttactgt	1140
20	acatcaatct	atgcataaat	ggcagcttgt	ttcttgagc	cactgtctaa	attttgtttt	1200
	tatagaaatt	ttttatactg	attggttcat	agatggtcag	ttttgtacac	agactgaaca	1260
	atacagact	ttgcaaaaaa	tgagtgtagc	attgttttaa	cattgtgtgt	taacacctgt	1320
	tctttgtaat	tgggttgtgg	tgcattttgc	actacctgga	gttacagttt	tcaatctgtc	1380
	agtaaataaa	gtgtccctta	acttcaaaaa	aaaaaaaaaa			
25	<210>	26					
	<211>	689					
	<212>	DNA					
	<213>	Human					
30	<400>	26					
	aaacaacaa	aaaaaaagtt	agtactgtat	atgtaaatac	tagcttttca	atgtgtctata	60
	caaacaatta	tagcacatcc	ttcctttttac	tctgtctcac	ctccttttagg	tgagtacttc	120
35	cttaaaataag	tgctaaacat	acatatacgg	aacttgaaag	ctttgggttag	ccttgccctta	180
	ggtaatcagc	ctagttttaca	ctgtttccag	ggagtagttg	aattactata	aaccatttagc	240
	cacttgtctc	tgaccatttt	atcacaccag	gacagggctc	ctcaacctgg	gcgctactgt	300
	catttggggc	caggtgatcc	ttccttgcaa	ggcgtgtcct	gtacctgccc	ggcgcgccgc	360
	tcgaagcgtg	gtcgcggccg	aggtactgaa	aggaccaagg	agctctggct	gccctcagga	420
40	attccaaatg	accgaaggaa	caaagcttca	gggctctggg	tggtgtctcc	cactattcag	480
	gaggtggctg	gaggtaacgc	agcttcattt	cgtccagtc	tttccagtat	ttaaagttgt	540
	tgtcaagatg	ctgcattaaa	tcaggcaggt	ctacaaaggc	atcccaagca	tcaaacatgt	600
	ctgtgatgaa	gtaatcaatg	aaacaccgga	acctccgacc	acctcctgaa	tagtgggaga	660
	cacacccaga	gcctgaagtt	tgtccttcg				
45	<210>	27					
	<211>	471					
	<212>	DNA					
	<213>	Human					
50	<400>	27					
	tccagcggcg	atgaagtttg	agattggcca	ggccctgtac	ctgggcttca	tctccttcgt	60
	ccctctcgct	catttggtggc	accctgcttt	gcctgtcctg	ccaggacgag	gcaccctaca	120
55	agccctaacc	caggccccgc	ccaggggccac	cacgaccact	gcaaacaccg	cacctgccta	180
	ccagccacca	gctgcctaca	aagacaatcg	ggccccctca	gtgacctcgg	ccaccacagc	240
	gggtacagcg	tgaacgacta	cgtgtgagtc	cccacagcct	gcttctcccc	tgggctgctg	300
	tgggctggtt	cccggcgga	ctgtcaatgg	aggcaggggt	tccagcacaa	agtttacttc	360
	tgggcaattt	ttgtatccaa	ggaaataatg	tgaatgcgag	gaaatgtctt	tagagcacag	420
60	ggacagaggg	ggaaataaga	ggaggagaaa	gctctctata	ccaagactg	a	
	<210>	28					
	<211>	929					
	<212>	DNA					
	<213>	Human					
65	<400>	28					



	ggtgaactca	gtgcattggg	ccaatgggtc	gacacagggt	ctgccagcca	caaccatcct	60
	gctgcttctg	acggtttgge	tgctgggtgg	ctttcccctc	actgtcattg	gaggcatctt	120
5	tggaagaac	aacgccagcc	cctttgatgc	accctgtcgc	accaagaaca	tcgcccggga	180
	gattccaccc	cagccctggt	acaagtctac	tgcatccac	atgactgttg	gaggcttcct	240
	gcctttcagt	gccatctctg	tgagagctga	ctacatcttt	gccacagtat	ggggctcgga	300
	gcagtacact	ttgtacggca	tcctcttctt	tgtcttcgcc	atcctgctga	gtgtgggggc	360
	ttgcatctcc	attgactca	cctacttcca	gtgtgtctgg	gaggattacc	gctgggtgtg	420
10	gcgatctgtg	ctgagtgttg	gctccaccgg	cctcttcac	ttcctctact	cagttttcta	480
	ttatgcccg	cgctccaaca	tgtctggggc	agtacagaca	gtagagtctt	tcggctactc	540
	cttactcact	ggttatgtct	tcttcctcat	gctgggcacc	atctcctttt	tttcttcctt	600
	aaagttcatc	cggtatatct	atgttaacct	caagatggac	tgagtctgt	atggcagaac	660
	tattgctgtt	ctctcccttt	cttcatgccc	tgttgaactc	tcctaccagc	ttctcttctg	720
15	attgactgaa	ttgtgtgatg	gcattgttgc	cttccctttt	tccctttggg	cattccttcc	780
	ccagagagg	cctggaaatt	ataaatctct	atcacataag	gattatata	ttgaactttt	840
	taagttgcct	ttagtttttg	tcctgatttt	tctttttaca	attacaaaa	taaaatttat	900
	taagaaaaag	aaaaaaaaa	aaaaaaaaa				
20	<210> 29						
	<211> 1775						
	<212> DNA						
	<213> Human						
25	<400> 29						
	gaacgtgatg	ggaacttttg	gaggatgtct	gagaaaaatg	ccgaagggat	tttggccaac	60
	accagaaaac	gccaatgtcc	taggaattcc	ctcccaaaat	gcttcccaaa	aaattactca	120
	ttgacaattc	aaattgcact	tggtgtggcg	cagcccgggc	ggccttcagt	ccgtgtgggg	180
30	cgcccgcgtg	gcctttctct	cgtaggactc	cccaaaactc	ttcactctgc	gtttatccac	240
	aggataaagc	caccgctggt	acaggtagac	cagaaacacc	acgtcgtccc	ggaagcaggc	300
	cagccggtga	gacgtgggca	tggtgatgat	gaaggcaaag	acgtcatcaa	tgaaggtgtt	360
	gaaagccttg	taggtgaagg	ccttcagggg	cagatgtgcc	actgacttca	actttagttt	420
	cacaagagag	tggggcagca	tgaagaggaa	accaaaggca	tagaccccg	tgacgaagct	480
35	gttgatatac	caggagtagc	agctcttata	tttgatattc	aggagtgaat	agacagcacc	540
	cccagacacg	agagggtaca	gcaggtagat	caagtacttc	atggcctgag	tatcgtactc	600
	ctcgggtttt	ctctcagatt	cgctgtaagt	gccaaactga	aattcgggca	tcaggcctct	660
	ccaaaaata	gtcatcttca	atgccttctt	cactttccac	agctcaatgg	cggtcccaac	720
	accgcgcggg	accagacca	gcaggctcgt	ctgctcgtcc	agcaggaaca	gaaagatgac	780
40	cacgggtgctg	aagcagcgcc	agagcactgc	cttggtggac	atgccgatca	tgctcttctt	840
	cttcttccag	aaactgatgt	cattttttaa	ggccaggaaa	tcaaagagaa	gatggaacgc	900
	tgcgacaaag	aaggtcagcg	ccaggaagta	taagttggta	tctacaaaaa	ttcctttcac	960
	ctcatcagca	tctttctctg	aaaaccggaa	ctgctgcagg	gagtacacgg	cgtcctgcat	1020
	gtgatccag	aagcgcagcc	gccccagtga	gaccttgtcg	taggacacgg	tgaggggcag	1080
45	ctcgggtggtg	gagcgggtta	tgaccatcag	gtccttcacg	cggttgctga	gctgggtcgat	1140
	gaacaggatg	ggcaggtaat	gcacggtttt	ccccagctgg	atcatcttca	tgtagccgatg	1200
	acatcgggca	ggcaggggag	acccgtcaaa	gacaaagtgt	tccgccatca	cggtcagcgc	1260
	cagccgcggg	cgccagtggg	acactggctc	atccagggca	ctcgtcggct	tcttctccgc	1320
	ctcgtatctgc	tgtgtatcag	actccccggt	gagcagggtg	atttcttctg	gcttggggac	1380
50	catgtagggtg	gtcagaggac	tgaccaggtg	cacctgcttc	ccgtcgtgcc	acggcaggac	1440
	cccagcgtga	tgaggaaga	tgtaggcata	cagcgtccca	ttgtttctcg	ttttcttttg	1500
	tacagaaaca	ttactgtcc	tttcaaattt	ggactccaca	tcaaagtctt	ccacattcaa	1560
	gaccaggtcg	atgttgttct	cagcaccacg	gtgggacctc	gtcgtgggtg	acacgctcag	1620
	ctgcagcttg	ggccgcccgc	ccaggtaggg	ctggatgcag	ttggcgtcgc	cggagcacgg	1680
55	gcgggtgtag	acgatgccgt	acatgacca	gcagggtgtg	accacgtaga	ccacgaacac	1740
	gcccaccacc	aagctggtga	aggagctgcg	gcccc			
60	<210> 30						
	<211> 1546						
	<212> DNA						
	<213> Human						
	<400> 30						
65	aaaataagta	ggaatgggca	gtgggtattc	acattcacta	caccttttcc	atttgcta	60
	aaggccctgc	caggctggga	gggaattgtc	cctgcctgct	tctggagaaa	gaagatattg	120

	acaccatcta	cgggcaccat	ggaactgctt	caagtgacca	ttctttttct	tctgcccagt	180
	atgtgcagca	gtaacagcac	agggtgttta	gaggcagcta	ataattcact	tggtgttact	240
	acaacaaaac	catctataac	aacaccaaac	acagaatcat	tacagaaaaa	tggtgtcaca	300
5	ccaacaactg	gaacaactcc	taaaggaaca	atcaccaatg	aattacttaa	aatgtctctg	360
	atgtcaacag	ctactttttt	aacaagtaaa	gatgaaggat	tgaaagccac	aaccactgat	420
	gtcaggaaga	atgactccat	catttcaaac	gtaacagtaa	caagtgttac	acttccaaat	480
	gctgtttcaa	cattacaaag	ttccaaaccc	aagactgaaa	ctcagagttc	aattaaaaa	540
	acagaaatac	caggtagtgt	tctacaacca	gatgcatcac	cttctaaaac	tggtacatta	600
10	acctcaatac	cagttacaat	tccagaaaaa	acctcacagt	ctcaagtaat	aggcactgag	660
	gggtggaaaa	atgcaagcac	ttcagcaacc	agccggtctt	attccagtat	tattttgccc	720
	gtgggtattg	cttttgattgt	aataacactt	tcagtatttg	ttctgggtgg	tttgtaccga	780
	atgtgctgga	aggcagatcc	gggcacacca	gaaaatggaa	atgatcaacc	tcagtctgat	840
	aaagagagcg	tgaagcttct	taccgttaag	acaatttctc	atgagtctgg	tgagcactct	900
15	gcacaaggaa	aaaccaagaa	ctgacagctt	gaggaattct	ctccacacct	aggcaataat	960
	tacgcttaat	cttcagcttc	tatgcaccaa	gcgtggaaaa	ggagaaagtc	ctgcagaatc	1020
	aatcccgact	tccatacctg	ctgctggact	gtaccagacg	tctgtcccag	taaagtgatg	1080
	tccagctgac	atgcaataat	ttgatggaat	caaaaagaac	cccggggctc	tcctgttctc	1140
	tcacatttaa	aaattccatt	actccattta	caggagcgtt	cctaggaaaa	ggaatttttag	1200
20	gaggagaatt	tgtgagcagt	gaatctgaca	gccacaggag	tggtgctcgt	gataggcatg	1260
	actttcctta	atgttttaag	ttttccgggc	caagaatttt	tatccatgaa	gactttccta	1320
	cttttctcgg	tgttcttata	ttactctactg	ttagtattta	ttgtttacca	ctatgttaat	1380
	gcagggaaaa	gttgacagtg	tattattaaa	tattaggtag	aaatcatacc	atgctacttt	1440
	gtacatatata	gtattttatt	cctgctttcg	tggtactttt	aataaataac	tactgtactc	1500
25	aatactctaa	aaatactata	acatgactgt	gaaaatggca	aaaaaa		
	<210>	31					
	<211>	750					
	<212>	DNA					
	<213>	Human					
30							
	<400>	31					
	cacttgggca	ccccattttt	ctaaaaaaat	ggaaatctgg	agggcaaaaa	aggtgtgctg	60
35	aaggggaagt	cctctgatgg	ccccaaaaac	ttcttccaaa	ctagtgtagg	aatggaaatg	120
	atagcaaatg	gatccttttt	ggcctccttt	ggagcatgcc	ttccctatct	tatccttggc	180
	cccactaaag	cagaacgtta	cggatatctt	tggttttgcc	attggatgcc	tatctggcca	240
	aacagccttt	ccctaattgg	aaaatgcagt	cctgttttaa	acctttgatt	tacgactact	300
	tgtacatgct	tgctcattac	aattttgaca	ttttttacat	agtgaagacc	ccaaacatat	360
40	cagtgaacaa	tgacaagatc	ataaagaaca	gtatcatatt	attatttagt	cgcttttaca	420
	gtggcaagcc	aattttgaaa	tatctcattt	aaaactcaga	cccaattcac	tgagtataac	480
	ttttaatagc	ttcctcagca	cactattttc	catgcattaa	atatgataaa	ataatctatc	540
	actgccatc	ggctctgtta	aaaggaagtc	tgaatacaga	gccacaaca	ctaaaattgt	600
	ttttctagct	acaaagtata	gcacatcaaa	cacagacacg	atttggactc	cctgacaggt	660
45	ggattggaaa	acggtgttta	aagagaagag	aacattttta	cataaatgtc	attaagaatc	720
	ccaaaggcct	tatttgtcac	caccgtcccg				
	<210>	32					
	<211>	1620					
	<212>	DNA					
50	<213>	Human					
	<400>	32					
	gcaattcccc	cctcccacta	aacgactccc	agtaattatg	tttacaaccc	attggatgca	60
55	gtgcagccat	tcataagaac	cttggtgccc	cagaaaaatc	tgctcctttt	ggtaccaaac	120
	ctgagggtct	ttggaagata	atgtagaaaa	ccactaccta	ttgaaggcct	gttttggcta	180
	atctgtgcaa	actctgatga	tactgcctt	atgtggattc	ttttccacac	tgctttcatt	240
	tttaagtata	aagacttaga	aaactagaat	aatgctttta	caaataatta	aaagtatgtg	300
60	atgttctggg	ttttttcctt	cttttttagaa	ccccgcctcc	atttaaaaaa	ttaaaaaaa	360
	aaaaaaaaact	tttaacattt	aaaaaataaa	aattaacaaa	atttcaacta	ttccaggaca	420
	cgctggcatt	tggaactcaat	gaaaagggca	cctaagaaaa	ataaggctga	ctgaatgttt	480
	tccataattt	tcacacaata	acagtccttt	tctatccage	ttgccttcca	tttatctcta	540
	gggttagctt	ttcaggcaac	atccttggtc	attgccaga	aagtacctga	gctatcagtg	600
	attggaatgg	cacaggaaac	cgaatcacat	gggtgccctc	cccttggttt	tcaagtatct	660
65	tggaagtgtg	cacaaaaatt	aggatcatgcc	ttcagtgctt	tggtctttta	acctaccctt	720
	tgacaatcag	gtgctaata	ttgtatacta	ttaaaaccag	cacataagta	ttgtaaatgt	780

	gtgttcctcc	taggttgga	gaaatgtctt	tccttctatc	tgggtcctgt	taaagcgggt	840
	gtcagttgtg	tcttttcacc	tcgatttgtg	aattaataga	attgggggga	gaggaaatga	900
	tgatgtcaat	taagtttcag	gtttggcatg	atcatcattc	tcgatgatat	tctcactttg	960
5	tcgcaaattc	gcccttatcg	taagaacaag	tttcagaatt	ttccctccac	tatacgactc	1020
	cagtattatg	tttacaatcc	attggatgag	tgacagcatta	taagaccttg	gtgcccagaa	1080
	aaatctgtcc	tttttggtag	caaacctgag	gtcttttggg	agataatgta	gaaaaccact	1140
	acctattgaa	ggcctgtttt	ggctaactctg	tgcaaaactct	gatgataacct	gcttatgtgg	1200
	attctttttc	acactgtctt	cattttttaag	tataaagact	tagaaaacta	gaataatgct	1260
10	tttacaata	attaaaagta	tgtgatgttc	tgggtttttt	ccttcttttt	agaaccctgt	1320
	atttaaacaa	gccttctttt	taagtcttgt	ttgaaattta	agtctcagat	cttctgggata	1380
	ccaaatcaaa	aacccaacgc	gtaaaacagg	gcagtatattg	tgttcctaata	tttaaaaagc	1440
	tttatgtata	ctctataaat	atagatgcat	aaacaacact	tccccttgag	tagcacatca	1500
	acatacagca	ttgtacatta	caatgaaaat	gtgtaactta	agggtattat	atatataaat	1560
15	acatatatac	ctttgtaacc	tttatactgt	aaataaaaaa	gttgcttttag	tcaaaaaaaa	1620
	<210> 33						
	<211> 2968						
	<212> DNA						
	<213> Human						
20	<400> 33						
	gaaaaagtag	aaggaaacac	agttcatata	gaagtaaaag	aaaaccctga	agaggaggag	60
25	gaggaggaag	aagaggaaga	agaagatgaa	gaaagtgaag	aggaggagga	agaggaggga	120
	gaaagtgaag	gcagtgaagg	tgatgaggaa	gatgaaaagg	tgtcagatga	gaaggattca	180
	gggaagacat	tagataaaaa	gccaaagtaa	gaaatgagct	cagattctga	atatgactct	240
	gatgatgatc	ggactaaaga	agaaagggct	tatgacaaag	caaaacggag	gattgagaaa	300
	cggcgacttg	aacatagtaa	aaatgtaaac	accgaaaagc	taagagcccc	tattatctgc	360
30	gtacttgggc	atgtggacac	agggaagaca	aaaattctag	ataagctccg	tcacacacat	420
	gtacaagatg	gtgaagcagg	tggatcaca	caacaaattg	gggccaccaa	tgttctctct	480
	gaagctatta	atgaacagac	taagatgatt	aaaaattttg	atagagagaa	tgtacggatt	540
	ccaggaatgc	taattattga	tactcctggg	catgaatctt	tcagtaatct	gagaaataga	600
	ggaagctctc	tttgtgacat	tgccattttt	gttgttgata	ttatgcatgg	tttggagccc	660
35	cagacaattg	agtctatcaa	ccttctcaaa	cttaaaaaat	gtcccttcat	tgttgactct	720
	aataagattg	ataggttata	tgattggaaa	aagagtcctg	actctgatgt	ggctgtact	780
	ttaaagaagc	agaaaaagaa	tacaaaagat	gaatttgagg	agcgagcaaa	ggctattatt	840
	gtagaatttg	cacagcaggg	tttgaatgct	gctttgtttt	atgagaataa	agatccccgc	900
	acttttgtgt	cttttggtacc	tacctctgca	catactgggtg	atggcatggg	aagtctgatc	960
40	taccttcttg	tagagttaac	tcagaccatg	ttgagcaaga	gacttgcaca	ctgtgaagag	1020
	ctgagagcac	aggtgatgga	ggttaaagct	ctcccgggga	tgggcaccac	tatagatgtc	1080
	atcttgatca	atgggcgttt	gaaggaagga	gatacaatca	ttgttctctg	agtagaaggg	1140
	cccattgtaa	ctcagattcg	aggcctcctg	ttacctcttc	ctatgaagga	attacgagtg	1200
	aagaaccagt	atgaaaagca	taaagaagta	gaagcagctc	agggggtaaa	gattcttgga	1260
45	aaagacctgg	agaaaacatt	ggctggttta	cccctccttg	tggcttataa	agaagatgaa	1320
	atccctgttc	ttaaagatga	attgatccat	gagttaaagc	agacactaaa	tgctatcaaa	1380
	ttagaagaaa	aaggagtcta	tgtccaggca	tctacactgg	gttcttttga	agctctactg	1440
	gaatttctga	aaacatcaga	agtgccttat	gcagggaatta	acattggccc	agtgcataaa	1500
	aaagatgtta	tgaaggcttc	agtgatgttg	gaacatgacc	ctcagtatgc	agtaattttg	1560
50	gccttcgatg	tgagaattga	acgagatgca	caagaaatgg	ctgatagttt	aggagttaga	1620
	atttttagtg	cagaaattat	ttatcattta	tttgatgcct	ttacaaaata	tagacaagac	1680
	tacaagaaac	agaaacaaga	agaatttaag	cacatagcag	tatttccctg	caagataaaa	1740
	atcctccctc	agtacatttt	taattctcga	gatccgatag	tgatgggggt	gacgggtgga	1800
	gcaggtcagg	tgaacacagg	gacacccatg	tgtgtcccaa	gcaaaaattt	tgttgacatc	1860
55	ggaatagtaa	caagtattga	aataaaccat	aaacaagtgg	atgttgcaaa	aaaaggacaa	1920
	gaagtttgtg	taaaaataga	acctatccct	ggtgagtcac	ccaaaatgtt	tggaagacat	1980
	tttgaagcta	cagatattct	tgtagtaag	atcagccggc	agtccattga	tgactcaaaa	2040
	gactggttca	gagatgaaat	gcagaagagt	gactggcagc	ttattgtgga	gctgaagaaa	2100
	gtatttgaaa	tcactctaatt	ttttcacatg	gagcaggaac	tgagtagaat	gcaatactgt	2160
60	gttgtaatat	cccaacaaaa	atcagacaaa	aatggaaca	gacgtatttg	gacactgatg	2220
	gacttaagta	tggaagggaag	gtataaaatg	ttttccatga	gaaaccaaga	2280	
	aacttacact	ggtttgacag	tggtcagttt	catgtcccca	cagttccaat	gtgcctgttc	2340
	actcacctct	cccttcccca	acccttctct	acttggtgcg	tgttttaaag	tttgcccttc	2400
	cccaattttg	gatttttatt	acagatctaa	agctctttcg	attttatact	gattaaatca	2460
65	gtactgcagt	atttgattaa	aaaaaaaaaa	gcagattttg	tgattcttgg	gacttttttg	2520
	acgtaagaaa	tacttcttta	tttatgcata	ttcttcccac	agtgattttt	ccagcattct	2580
	tctgccatat	gcctttgagg	cttttataaa	atagaaaatt	aggcattctg	atatttcttt	2640

agctgctttg tgtgaaacca tgggtgtaaaa gcacagctgg ctgcttttta ctgcttgtgt 2700  
 agtcacgagt ccattgtaat catcacaatt ctaaaccaaa ctaccaataa agaaaacaga 2760  
 catccaccag taagcaagct ctgtaggctt tccatgggta gtggtagctt ctctcccaca 2820  
 5 agttgtcttc ctaggacaag gaattatctt aacaaactaa actatccatc acactacctt 2880  
 ggtatgccag cacctgggta acagtaggag attttataca ttaatctgat ctgtttaatc 2940  
 tgatcggttt agtagagatt ttatacat

&lt;210&gt; 34

&lt;211&gt; 6011

10 &lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 34

15

acggggcgcc ggacgacccg cacatcttat cctccacgcc ccaactcgac tccggagcggg 60  
 accgccccgg actccccctc gggccggcca ctcgaggagt gaggagagag gccgccggcc 120  
 20 cggttgagc cgagcgagc acccccgcg ccccgcgcca gaagtgtgtg tgaaccgggc 180  
 tgccgggaga aacttttttc ttttttcccc ctctcccggg agagtctctg gaggagggag 240  
 ggaactcccc cggcccaagg ctcgtgggct cggggctcgc cggccgcaga agggggcggg 300  
 tccgccccgc aggggaggcg cccccgggga cccgagaggg gggtaggagc cgcgggctgc 360  
 25 tgggtgcggcg gcggcagcgt gtgccccgcg caggggaggc gccgccccgc tcccggcccg 420  
 gctgcgagga ggaggcgcg gcggcgagc aggtgtact tgggtggcgg ggacaggggg 480  
 ttggcgggct gcgggcacct cctggtctcg ctgctggggc tgctgctgct gccggcgcg 540  
 tccggcaccg gggcgctggt ctgcctgccc tgtgacgagt ccaagtgcga ggagcccagg 600  
 aaccgccccg ggagcatcgt gcagggcgctc tcgggctgct gctacacgtg cgcagccag 660  
 30 gggaaacgaga gctgcggcgg caacttcggg atttacggaa cctgcgaccg ggggctgcgt 720  
 tgtgtcatcc gcccccgcct caatggcgac tccctcaccg agtacgaagc gggcggttgc 780  
 gaagatgaga actggactga tgaccaactg ctgtggttta aaccatgcaa tgaaaacctt 840  
 attgctggct gcaatataat caatgggaaa tgtgaatgta acaccattcg aacctgcagc 900  
 aatccctttg agtttccaag tcaggatatg tgcttttcag ctttaaagag aattgaagaa 960  
 35 gagaagccag attgtccaa ggcccgctgt gaagtccagt tctctccacg ttgtcctgaa 1020  
 gattctgttc tgatcgagg ttatgtctct cctggggagt gctgtccctt acccagccgc 1080  
 tgcgtgtgca accccgcagg ctgtctgcgc ctgtggttga agccgggaaa cctgaacata 1140  
 ctagtgtcaa aagcctcagg gaagccggga gagtgtgtg acctctatga gtgcaacca 1200  
 gttttcggcg tggactgcag gactgtggaa tgccctactg ttcagcagac cgcgtgtccc 1260  
 40 ccggacagct atgaaactca agtcagacta actgcagatg gttgctgtac tttgccaaca 1320  
 agatgcgagt gtctctctgg cttatgtggt ttccccgtgt gtgaggtggg atccactccc 1380  
 cgcatagtct ctcgtggcga tgggacacct ggaaagtgt gtgatgtctt tgaatgtgtt 1440  
 aatgatacaa agccagcctg cgtatttaac aatgtggaat attatgatgg agacatgttt 1500  
 cgaatggaca actgtcgggt ctgtcgatgc caagggggcg ttgccatctg cttcaccgcc 1560  
 45 cagtgtggtg agataaactg cgagaggtag tacgtgcccc aaggagagtg ctgcccagtg 1620  
 tgtgaagatc cagtgtatcc ttttaataat cccgctggct gctatgccaa tggcctgatc 1680  
 cttgccacag gagaccgtg gcgggaagac cagtgcacat tctgccagtg cgtcaacggt 1740  
 gaacgccact gcgttgcgac cgtctgcgga gacacctgca caaacctgt gaaagtgcct 1800  
 ggggagtggt gccctgtgtg cgaagaacca accatcatca cagttgatcc acctgcattg 1860  
 50 ggggagttat caaactgcac tctgacacgg aaggactgca ttaatggttt caaacgcgat 1920  
 cacaatgggt gtcggacctg tcagtgcata aacaccagg aactatgttc agaacgtaaa 1980  
 caaggctgca ccttgaaactg tcccttcggt ttccttactg atgccccaaa ctgtgagatc 2040  
 tgtgagtgcc gcccaaggcc caagaagtgc agaccataa tctgtgacaa gtattgtcca 2100  
 cttggattgc tgaagaataa gcacggctgt gacatctgtc gctgtaagaa atgtccagag 2160  
 55 ctctcatgca gtaagatctg ccccttgggt ttccagcagg acagtcacgg ctgtcttate 2220  
 tgcaagtgca gagaggcctc tgcttcagct gggccaccca tcctgtcggg cacttgtctc 2280  
 accgtggatg gtcattcatca taaaaatgag gagagctggc acgatgggtg ccgggaatgc 2340  
 tactgtctca atggacggga aatgtgtgcc ctgatcacct gccgggtgcc tgccgtgtgc 2400  
 aaccaccaca ttcaccctgg acagtgtctc ccatcatgtg cagatgactt tgtggtgcag 2460  
 aagccagagc tcagtactcc ctccatttgc cagccccctg gaggagaata ctttgtggaa 2520  
 60 ggagaaacgt ggaacattga ctccgtactt cagtgcacct gccacagcgg acgggtgtctg 2580  
 tgtgagacag aggtgtgccc accgtgtctc tgccagaacc cctcacgcac ccaggattcc 2640  
 tgctgccac agtgtacaga tcaacctttt cggccttcct tgtcccgcaa taacagcgta 2700  
 cctaattact gcaaaaatga tgaaggggat atattcctgg cagctgagtc ctggaagcct 2760  
 gacgtttgta ccagctgcac ctgcattgat agcgtaatga gctgtttctc tgagtcctgc 2820  
 65 ccttctgtat cctgtgaaag acctgtcttg agaaaaggcc agtgttgtcc ctactgcata 2880  
 aaagacacaa ttccaaagaa ggtggtgtgc cacttcagtg ggaaggccta tgccgacgag 2940

	gagcgggtggg	accttgacag	ctgcacccac	tgtactgtcc	tgcagggcca	gaccctctgc	3000
	tcgaccgtca	gctgcccccc	tctgccctgt	gttgagccca	tcaacgtgga	aggaagttgc	3060
	tgcccaatgt	gtccagaaat	gtatgtccca	gaaccaacca	atatacccat	tgagaagaca	3120
5	aaccatcgag	gagaggttga	cctggaggtt	ccctgtggc	ccacgcctag	tgaaaatgat	3180
	atcgteccatc	tccctagaga	tatgggtcac	ctccaggtag	attacagaga	taacaggctg	3240
	cacccaagtg	aagattcttc	actggactcc	attgcctcag	ttgtggttcc	cataattata	3300
	tgctctctcta	ttataatagc	attcctattc	atcaatcaga	agaaacagtg	gataccactg	3360
	ctttgtctggt	atcgaacacc	aactaagcct	tcttccttaa	ataatcagct	agtatctgtg	3420
10	gactgcaaga	aaggaaccag	agtccaggtg	gacagttccc	agagaatgct	aagaattgca	3480
	gaaccagatg	caagattcag	tggcttctac	agcatgcaaa	aacagaacca	tctacaggga	3540
	gacaatttct	accaaacagt	gtgaagaaag	gcaactagga	tgaggtttca	aaagacggaa	3600
	gacgactaaa	tctgtctctaa	aaagtaaact	agaatttgtg	cacttgctta	gtggattgta	3660
	ttggattgtg	acttgatgta	cagcgctaag	accttactgg	gatgggctct	gtctacagca	3720
	atgtgcagaa	caagcattcc	cacttttcct	caagataact	gaccaagtgt	tttcttagaa	3780
15	ccaaagtttt	taaagtgtgt	aagatatatt	tgccgtgaag	atagctgtag	agatatttgg	3840
	gggtggggaca	gtgagtttgg	atgggggaaag	gggtgggagg	gtggtgttgg	gaagaaaaat	3900
	tggtcagctt	ggctcgggga	gaaacctggg	aacataaaag	cagttcagtg	gcccagaggt	3960
	tatttttttc	ctattgctct	gaagactgca	ctggttgctg	caaagctcag	gcctgaatga	4020
	gcaggaaaca	aaaaaggcct	tgcgacccag	ctgccataac	caccttagaa	ctaccagacg	4080
20	agcacatcag	aaccttttga	cagccatccc	aggtctaaag	ccacaagttt	cttttctata	4140
	cagtcacaac	tgcagtagga	agtgaggaag	ccagagaaat	gcgatagcgg	catttctcta	4200
	aagcgggtta	ttaaggatat	atacagttac	actttttgct	gcttttattt	tcttccaagc	4260
	caatcaatca	gccagttcct	agcagagtca	gcacatgaac	aagatctaag	tcatttcttg	4320
	atgtgagcac	tggagctttt	tttttttaca	acgtgacagg	aagaggaggg	agagggtgac	4380
25	gaacaccagg	catttccagg	ggctatatatt	cactgtttgt	tggtgctttg	ttctgttata	4440
	ttgttggttg	ttcatagttt	ttgttgaagc	tctagcttaa	gaagaaactt	tttttaaaaa	4500
	gactgtttgg	ggattctttt	tccttattat	atactgattc	tacaaaatag	aaactacttc	4560
	attttaattg	tatattattc	aagcaccttt	gttgaagctc	aaaaaaaaatg	atgcctcttt	4620
	aaacttttagc	aattatagga	gtattttatgt	aactatctta	tgcttcaaaa	aacaaaagta	4680
30	tttgtgtgca	tgtgtatata	atatatatat	atacatatat	atltatacac	atacaattta	4740
	tgttttccctg	ttgaatgtat	ttttaaccag	aaataaccag	aacaaaggca	gataaacagg	4800
	cattccatag	cagtgccttt	gatcacttac	aaattttttg	aataacacaa	aatctcattc	4860
	tacctgcagt	ttaattggaa	agatgtgtgt	gtgagagtat	gtatgtgtgt	gtgtgtgtgt	4920
	gtgtgtgcgc	gcgcacgcac	gccttgagca	gtcagcattg	cacctgctat	ggagaagggt	4980
35	attcctttat	taaaatcttc	ctcatttgga	tttgctttca	gttggttttc	aatttgctca	5040
	ctggccagag	acattgatgg	cagttcttat	ctgcacact	aatcagctcc	tggtttttt	5100
	tttttttttt	tcaaacaatg	gtttgaaaca	actactggaa	tattgtccac	aataagctgg	5160
	aagtttggtg	tagtatgcct	caaataatac	tgactgtata	ctatagtggg	aacttttcaa	5220
	acagccctta	gcacttttat	actaattaac	ccatttggtg	attgagtttt	cttttaaaaa	5280
40	tgcttggtgt	gaaagacaca	gatacccgat	atgcttaacg	tgaaaagaaa	atgtgttctg	5340
	ttttgtaaag	gaactttcaa	gtattgttgt	aaataacttg	acagagggtg	ctgaacttta	5400
	aaaaaaatta	atttattatt	ataatgacct	aattttattaa	tctgaagatt	aaccattttt	5460
	ttgtcttaga	atatcaaaaa	gaaaaagaaa	aaggtgttct	agctgtttgc	atcaaaggaa	5520
	aaaaagattt	attatcaagg	ggcaatattt	ttatcttttc	caaaataaat	ttgttaatga	5580
45	tacattacaa	aaatagattg	acatcagcct	gattagtata	aattttgttg	gtaattaatc	5640
	cattcctggc	ataaaaagtc	tttatcaaaa	aaaattgtag	atgcttgctt	tttgtttttt	5700
	caatcatggc	catattatga	aaataactac	aggatatagg	acaagggtga	aattttttta	5760
	ttattatttt	aaagatatga	tttatcctga	gtgctgtatc	tattactctt	ttactttggg	5820
	tcctgttggtg	ctcttgtaaa	agaaaaatat	aatttcctga	agaataaaaat	agatatatgg	5880
50	cacttgagtg	gcacatagtg	tctacagttt	gtttttgttt	tcttcaaaaa	agctgtaaga	5940
	gaattatctg	caacttgatt	cttggcagga	aataaacatt	ttgagttgaa	atcaaaaaaa	6000
	aaaaaaaaaa	a					
55	<210>	34a					
	<211>	1036					
	<212>	DNA					
	<213>	Human					
60	<400>	34a					
	mylvagdrgl	agcghllvsl	lgllllpars	gtralvclpc	deskceepn	rpgsivqgvc	60
65	gccytcasqg	nescgggtfgi	ygtcdrglrc	virpplngds	lteyeagvce	denwtddqll	120
	gfkpcnenli	agcniingkc	ecntirtcsn	pfefpsqdmc	lsalkrieee	kpdcskarce	180
	vqfsprcped	svliegyapp	geccplpsrc	vcnpagclrk	vcqpgnlnil	vskasgkpgc	240

5 ccdlyeckpv fgvdcrvec ptvqgtacpp dsyetqvrllt adgcctlptr ceclsglclgf 300  
 pvcevgstpr ivsrgdgtpg kccdvfecvn dtkpacvfnn veyydgdmdfr mdncrfrcrq 360  
 ggvaicftaq cgeinceryy vpegeccpvc edpvypfnnp agcyanglil ahgdrwredd 420  
 10 ctfccqcnge rhcvatvcgq tctnpvkvpq eccpvceep iitvdppacg elsncctltrk 480  
 dcingfkrdh ngertcqcinq tgelcserkq gctlncpfgf ltdaqnceic ecrprpkkr 540  
 piicdkycpl gllknkhgdc icrckkcpel scskicplgf qqdshgcllc kreasasag 600  
 ppilsgtclt vdghhhknee swhdgcrecy cingremcal itcpvpacgn ptihpgqccp 660  
 scaddfvvqk pelstpsich apggeyfvveg etwnidsctq ctchsgrvlc etevcppllc 720  
 15 qnpsrtqdsq cpqctdqpfr pslsrnnsvp nyckndegdi flaaeswkpd vctscicids 780  
 viscfsepsc svscerpvlr kgqccpycik dtipkkvch fsgkayadee rwdldsccthc 840  
 yclgqgtlcs tvscpplpcv epinvegsc pmcpemyvpe ptnipiekt nhrgevdlevp 900  
 lwptpsendi vhlprdmghl qvdyrdnrhl psedssldsi asvvvpiiic lsiiiaflfi 960  
 nqkkqwipll cwyrtpkps slnnqlvsd ckkgtrvqv ssqmlriae pdarfsgfys 1020  
 20 mqkqnqlqad nfyqtv

&lt;210&gt; 35

&lt;211&gt; 716

&lt;212&gt; DNA

20 &lt;213&gt; Human

&lt;400&gt; 35

25 gcagtagctg gagggtcctg cagggggaaa gccaaccggg ccctgaagtc cggggcagtc 60  
 acccggggct cctgggcccgc tctgccgggc tggggctgag cagcgatcct gctttgtccc 120  
 agaagtcacg agggatcagc cccagaacac accctcctcc ccgggacgcc gcagctttct 180  
 ggaggctgag gaaggcatga agagtgggct ccacctgctg gccgactgag aaaagaattt 240  
 30 ccagaactcg gtcctatttt acagattgag aaactatggt tcaagaagag aggacggggc 300  
 ttgagggaaat ctcttgattc tccttatatg acctcaaact gaccatacta aacagtgtag 360  
 aagggtctttt taaggctcta aatgtcaggg tctcccatcc cctgatgcct gacttgtaca 420  
 gtcagtgtgg agtagacggg ttcctccacc cagggttgac tcagggggat gatctgggtc 480  
 ccattctggg cttaagaccc caaacaaggg ttttttcagc tccaggatct ggagcctcta 540  
 35 tctgggttagt gtcgtaacct ctgtgtgcct cccgttacc catctgtcca gtgagctcag 600  
 ccccatcca cctaacaggg tggccacagg gattactgag ggtaagacc ttagaactgg 660  
 gtctagcacc cgataagagc tcaataaatg ttgttccttt ccacatcaaa aaaaaa

&lt;210&gt; 36

&lt;211&gt; 395

&lt;212&gt; DNA

40 &lt;213&gt; Human

&lt;400&gt; 36

45 ccaatacttc attcttcatt ggtggagaag attgtagact tctaagcatt ttccaaataa 60  
 aaaagctatg atttgatttc caacttttaa acattgcatg tcctttgcca tttactacat 120  
 tctccaaaaa aaccttgaaa tgaagaaggc cacccttaaa atacttcaga ggctgaaaaat 180  
 atgattatta cattggaatc ctttagccta tgtgatattt ctttaacttt gcactttcac 240  
 50 gccagtaaaa accaaagtca gggttaacca tgtcatttta caaatgtta aaaccctaata 300  
 tgcagttcct tttttaaatt attttaaaga ttacttaaca acattagaca gtgcaaaaaa 360  
 agaagcaagg aaagcattct taattctacc atcct

&lt;210&gt; 37

&lt;211&gt; 134

&lt;212&gt; DNA

55 &lt;213&gt; Human

&lt;400&gt; 37

60 ccctcgagcg gccgcccggg caggtagctt taccaccgaa ttgttcactt gactttaaga 60  
 aaccataaaa gctgcctggc tttcagcaac aggcctatca acaccatggt gacttccat 120  
 aaggacacc gtgt

&lt;210&gt; 38

&lt;211&gt; 644

&lt;212&gt; DNA

65

&lt;213&gt; Human

&lt;400&gt; 38

```

5  aagcctgttg tcatggggga ggtggtggcg cttggtggcc actggcggcc gaggtagagg 60
   cagtggcgct tgagttggtc gggggcagcg gcagatttga ggcttaagca acttcttccg 120
   gggaagagtg ccagtgagc cactgtttaca attcaagatc ttgatctata tccatagatt 180
   ggaatatttg tgggccagca atcctcagac gcctcactta ggacaaatga ggaaactgag 240
10 gcttggtgaa gttacgaaac ttgtccaaaa tcacacaact tgtaaagggc acagccaaga 300
   ttcagagcca ggctgtaaaa attaaaatga acaaattacg gcaaagtttt aggagaaaga 360
   aggatgttta tgttcagag gccagtcgtc cacatcagtg gcagacagat gaagaaggcg 420
   ttgcgaccgg aaaatgtagc ttcccggtta agtaccttgg ccatgtagaa gttgatgaat 480
   caagaggaat gcacatctgt gaagatgctg taaaaagatt gaaagctgaa aggaagtctt 540
15 tcaaaggctt ctttgaaaaa actggaaaga aagcagttaa agcagtttct gtgggtctaa 600
   gcagatggac tcagaggttg tggatgaaaa actaaggacc tcat

```

&lt;210&gt; 39

&lt;211&gt; 657

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 39

```

25 ctttttgttt gggttttcca atgtagatgt ctcaagtgaat tgtgcagata tactttgttc 60
   cttatatggt caccagtgtt aattatggac aaatacatta aaacaagggt tcctggccca 120
   gcctccatc taatctcttt gatactcttg gaactctaagt ctgaggagcg atttctgaat 180
   tagccagtgt tgtaccaact ttctgttagg aattgtatta gaataacctt tctttttcag 240
   acctgctcag tgagacatct tggggaatga agtaggaaaa tagacatttg gtggaaaaac 300
30 agcaaaatga gaacattaaa aagactcatt caagtatgag tataaagggc atggaaattc 360
   tggtcctttg agcaaaatga gaagaaaaaa ttctgctcag cagtattcac tgtgttaaga 420
   ttttttgttt tttacacgaa tggaaaaaat atgtgtaagt ggtatagatt ttaatcagct 480
   aacagtcact ccagagattt tgatcagcac caattcctat agtagtaagt atttaaaagt 540
   taagaaatac tactacattt aacattataa agtagagttc tggacataac tgaaaattag 600
35 atgtttgctt caatagaaat ttgttccac ttgtattttc aacaaaatta tcggaac

```

&lt;210&gt; 40

&lt;211&gt; 1328

&lt;212&gt; DNA

&lt;213&gt; Human

40

&lt;400&gt; 40

```

45 acaattttta aataactagc aattaatcac agcatatcag gaaaaagtac acagtgaagt 60
   ctggttagtt tttgtaggct cattatggtt agggtcgcta agatgtatat aagaacctac 120
   ctatcatgct gtatgtatca ctcatccttc ttctcatgtt catgcatact cgggcatcat 180
   gctaataatg atccttttaa gcactctcaa ggaaacaaaa gggcctttta tttttataaa 240
   ggtaaaaaaa attcccaaaa tattttgcac tgaatgtacc aaagggtgaag ggacattaca 300
   atatgactaa cagcaactcc atcacttgag aagtataata gaaaatagct tctaaatcaa 360
50 acttccctca cagtgcctgt tctaccacta caaggactgt gcatctaagt aataattttt 420
   taagattcac tatatgtgat agtatgatat gcatttattt aaaatgcatt agactctctt 480
   ccatccatca aatactttac aggatggcat ttaatacaga tatttcgtat ttccccact 540
   gctttttatt tgtacagcat cattaaacac taagctcagt taaggagcca tcagcaaac 600
   tgaagagatc agtagtaaga attccatttt cctcatcag tgaagacacc acaaatgaa 660
   actcagaact atatttctaa gcctgcattt tcaactgatc ataattttct tagtaattt 720
55 aagagacagt tttctatgg catctccaaa actgcatgac atcactagtc ttacttctgc 780
   ttaattttat gagaaggat tcttcatttt aattgctttt gggattactc cacatcttgc 840
   tttatttctt gactaacag attttcaata gagtgaagt aaattggggg tcataaaagc 900
   attggattga catatggttt gccagcctat ggggtttacag gcattgcccc aacatttctt 960
60 tgagatctat atttataagc agccatggaa ttctatttat gggatgttgg caatcttaca 1020
   ttttatagag gtcatatgca tagttttcat aggtgttttg taagaactga ttgctctcct 1080
   gtgagtttaag ctatgtttac tactgggacc ctcaagagga ataccactta tgttacactc 1140
   ctgcactaaa ggcagctact gcagtgtaaa gaaatgttct gaaaaagggt tatagaaatc 1200
   tggaataaag aaagggaag ctctctgtat tctataattg gaagagaaaa aaagaaaaac 1260
65 ttttaactgg aaatgttagt ttgtacttat tgatcatgaa tacaagtata tatttaattt 1320
   tgaaaaaa

```

<210> 41  
 <211> 987  
 <212> DNA  
 <213> Human

5

<400> 41

aacagagact ggcacaggac ctcttcattg caggaagatg gtagtgtagg caggtaacat 60  
 10 tgagctcttt tcaaaaaagg agagctcttc ttcaagataa ggaagtggta gttatggtgg 120  
 taacccccgg ctatcagtcg ggatgggtgc caccctcct gctgtaggat ggaagcagcc 180  
 atggagtggg agggaggcgc aataagacac ccctccacag agcttggcat catgggaagc 240  
 tggttctacc tcttcctggc tcctttgttt aaaggcctgg ctgggagcct tccttttggg 300  
 tgtctttctc ttctccaacc aacagaaaag actgctcttc aaagggtggag ggtcttcatg 360  
 15 aaacacagct gccaggagcc caggcacagg gctggggggc tggaaaaagg agggcacaca 420  
 ggaggaggga ggagctggta gggagatgct ggcctttacct aagggtctcga aacaaggagg 480  
 gcagaatagg cagaggcctc tccgtcccag gccctttttt gacagatggc gggacggaaa 540  
 tgcaatagac cagcctgcaa gaaagacatg tgttttgatg acaggcagtg tggccgggtg 600  
 gaacaagcac aggccttggg atccaatgga ctgaatcaga accctaggcc tgccatctgt 660  
 20 cagccgggtg acctgggtca attttagcct ctaaaagcct cagtctcctt atctgcaaaa 720  
 tgaggcttgt gatacctgtt ttgaagggtt gctgagaaaa ttaaagataa gggatccaa 780  
 aatagtctac ggccatacca ccctgaacgt gcctaattctc gtaagctaag cagggtcagg 840  
 cctggttagt acctggatgg ggagagtatg gaaaacatac ctgccgcag ttggagtgg 900  
 actctgtctt aacagtagcg tggcacacag aaggcactca gtaaatactt gttgaataaa 960  
 25 tgaagtagcg atttggtgtg aaaaaaa

<210> 42  
 <211> 956  
 <212> DNA  
 <213> Human

30

<400> 42

eggacgggtg ggcggacgag tgggtgcagg agcagggcgg ctgccgactg ccccaaccaa 60  
 35 ggaaggagcc cctgagtcct cctgcgcctc catccatctg tccggccaga gccggcatcc 120  
 ttgcctgtct aaagccttaa ctaagactcc cgccccgggc tggccctgtg cagaccttac 180  
 tcaggggatg tttacctggt gctcgggaag ggaggggaag gggccgggga gggggcacgg 240  
 cagggcgtgtg gcagccacac gcaggcggcc agggcggcca gggacccaaa gcaggatgac 300  
 40 cagccacctc cagccactg cctccccga atgcatttgg aaccaaagtc taaactgagc 360  
 tcgcagcccc cgcgcctctc ctccgcctcc catcccgctt agcgtctgag acagatggac 420  
 gcaggccctg tccagcccc agtgcgctcg ttccggtccc cacagactgc cccagccaac 480  
 gagattgctg gaaaccaagt caggccaggt gggcggacaa aagggccagg tgcggcctgg 540  
 45 ggggaacgga tgctccgagg actggactgt tttttcaca catcggtgcc gcagcggtg 600  
 gaaggaaagg cagatgtaaa tgatgtgttg gtttacaggg tatatttttg ataccttcaa 660  
 tgaattaatt cagatgtttt acgcaaggaa ggacttacct agtattactg ctgctgtgct 720  
 tttgatctct gcttaccgtt caagaggcgt gtgcaggccg acagtcggtg accccatcac 780  
 tcgcaggacc aagggggagg ggactgctgg ctcacgcccc gctgtgtcct ccctccccctc 840  
 ccttccttgg gcagaatgaa ttcgatgcgt attctgtggc cgccatctgc gcagggtgg 900  
 ggtattctgt catttacaca cgtcgttcta attaaaaagc gaattatact ccaaaa

<210> 43  
 <211> 536  
 <212> DNA  
 <213> Human

55 <400> 43

aaataaacac ttccataaca ttttgttttc gaagtctatt aatgcaatcc cacttttttc 60  
 60 cccctagttt ctaaagtgtt aagagagggg aaaaaaggct caggatagtt ttcacctcac 120  
 agtgtagct gtcttttatt ttactcttgg aaatagagac tccattaggg ttttgacatt 180  
 ttgggaaccc agttttacca ttgtgtcagt aaaacaataa gatagtttga gagcatatga 240  
 tctaaataaa gacatttgaa gggttagttt gaattctaaa agtaggtaat agccaaatag 300  
 cattctcatc ccttaacaga caaaaactta tttgtcaaaa gaattagaaa aggtgaaaat 360  
 attttttcca gatgaaactt gtgccacttc caattgacta atgaaataca aggagacaga 420  
 65 ctggaaaaag tgggttatgc cacctttaaa accctttctg gtaaataatta tggtagctaa 480  
 aggggtggtt ccccgccacc tggacctgga caggtagggt tccgtggtta accagt



<210> 44  
 <211> 1630  
 <212> DNA  
 <213> Human

5

&lt;400&gt; 44

```

10  ggggagggac gagtatggaa ccctgaaggt agcaagtcca ggcactggcc tgaccatccg 60
    gctccctggg caccaagtcc caggcaggag cagctgtttt ccatcccttc ccagacaagc 120
    tctattttta tcacaatgac ctttagagag gtctcccagg ccagctcaag gtgtcccact 180
    atccccctctg gagggaagag gcaggaaaat tctccccggg tccctgtcat gctactttct 240
    ccatcccagt tcagactgtc caggacatct tatctgcagc cataagagaa ttataaggca 300
    gtgatttccc ttagggcccag gacttggggc tccagctcat ctgttccttc tggggccatt 360
    catggcagggt tctgggctca aagctgaact ggggagagaa gagatacaga gctaccatgt 420
15  gactttacct gattgccctc agtttggggt tgcttattgg gaaagagaga gacaaagagt 480
    tacttgttac gggaaatatg aaaagcatgg ccaggatgca tagaggagat tctagcaggg 540
    gacaggattg gctcagatga cccctgaggg ctcttccagt cttgaaatgc attccatgat 600
    attaggaagt cgggggtggg tgggtggtggt gggctagtgt ggtttgaatt taggggcccga 660
    tgagcttggg tacgtgagca ggggtgtaag ttagggtctg cctgtatttc tgggtcccct 720
20  ggaaatgtcc ccttcttcag tgtcagacct cagtcccagt gtccatatcg tgcccagaaa 780
    agtagacatt atccctgccc atcccttccc cagtgcactc tgacctagct agtgcctggt 840
    gcccagtgac ctggggggagc ctggctgcag gccctcactg gttccctaaa ccttgggtggc 900
    tgtgattcag gtcccagggt gggactcagg gaggaatatg gctgagttct gtagtttcca 960
    gagttggctg gtagagcctt ctagagggttc agaataatag cttcaggatc agctgggggt 1020
25  atggaattgg ctgaggatca aacgtatgta ggtgaaagga taccaggatg ttgctaaagg 1080
    tgagggacag tttgggtttg ggacttacca ggttgatggt agatctggaa cccccaagt 1140
    aggttgagg gagttaaggt cagtatggaa gatagggttg ggacaggggt ctttggaaat 1200
    aaagagtgc cttagagggt tccttggggc tcaggaatgc tcctgctgct gtgaagatga 1260
    gaaggtgctc ttactcagtt aatgatgagt gactatatct accaaagccc ctacctgctg 1320
30  ctgggtccct tgtagcacag gagactgggg ctaaggggccc ctcccaggga agggacacca 1380
    tcaggcctct ggctgaggca gtagcataga ggatccattt ctacctgcat ttcccagagg 1440
    actagcagga ggcagccttg agaaaccggc agttcccaag ccagcgctg gctgttctct 1500
    cattgtcact gccctctccc caacctctcc tctaaccac tagagattgc ctgtgtcctg 1560
35  cctcttgccct cttgtagaat gcagctctgg ccctcaataa atgcttctg cattcatctg 1620
    caaaaaaaaaa
  
```

<210> 45  
 <211> 169  
 <212> DNA  
 <213> Human

40

&lt;400&gt; 45

```

45  tcttttgctt ttagcttttt atttttgtat taacaggagt cttattacac ataggtctga 60
    taaaactggg ttatgatctt cagtctgatt ccagtgtgc ataactagat aacgtatgaa 120
    ggaaaaacga cgacgaacaa aaaagtaagt gcttgaaga cttagttga
  
```

<210> 46  
 <211> 769  
 <212> DNA  
 <213> Human

50

&lt;400&gt; 46

```

55  tgcaggctcat atttactatc ggcaataaaa ggaagcaaaag cagtattaag cagcgggtgga 60
    atttgtcgct ttcacttttt ataaagtgtc acataaaatg tcatatttcc aaatttaaaa 120
    acataactcc agttcttacc atgagaacag catgggtatc acgaaggatc ttcttgaaaa 180
    aaacaaaaac aaaaaacaaa aacaatgata tcttctgggt atcacatcaa atgagataca 240
    aaggtgtact aggcaatctt agagatctgg caacttattt tatatataag gcatctgtga 300
60  ccaagagacg ttatgaatta aatgtacaaa tgtattatgt ataaatgtat taaatgcaag 360
    cttcatataa tgacaccaat gtctctaagt tgctcagaga tcttgactgg ctgtggccct 420
    ggccagctcc ttctctgata gtctgattct gcttccatat ataggcagct cctgatcatc 480
    catgccagtg aatgagaaaa caagcatgga atatatataac ttttaacatta aaaaatgttt 540
    tattttgtaa taaaatcaaa tttcccattg aaaccttcaa aaactttgca gaatgaggtt 600
65  ttgatatatg tgtacaagta gtaccttctt agtgcaagaa aacatcatta tttctgtctg 660
    cctgcctttt tgttttttaa aatgaagact atcattgaaa caagtttgtc ttcagtatca 720
  
```

ggacatgttg acggagagga aaggtaggaa agggtaggg atagaagcc

<210> 47  
 <211> 2529  
 <212> DNA  
 <213> Human

<400> 47

10 tttagttcat agtaatgtaa aaccatttgt ttaattctaa atcaaatac tttcacaaca 60  
 gtgaaaatta gtgactggtt aaggtgtgcc actgtacata tcatcatttt ctgactgggg 120  
 tcaggacctg gtcctagtcc acaaggggtg caggaggagg gtggaggcta agaacacaga 180  
 aaacacacaa aagaaaggaa agctgccttg gcagaaggat gaggtggtga gcttgccgag 240  
 ggatggtggg aaggggggtc cctgttgggg ccgagccagg agtcccaagt cagctctcct 300  
 15 gccttactta gctcctggca gaggggtgagt ggggacctac gaggttcaaa atcaaattgc 360  
 atttggccag cctggcttta ctaacagggt ccagagtgct ctctgttggc tgagctctcc 420  
 tgggctcact ccatttcatt gaagagtcca aatgattcat tttcctacc acaacttttc 480  
 attattcttc tggaaaccca tttctgttga gtccatctga cttaagtcct ctctccctcc 540  
 actagttggg gccactgcac tgaggggggt ccaccaatt ctctctagag aagagacact 600  
 20 ccagaggccc ctgcaacttt gcggatttcc agaaggtgat aaaaagagca ctcttgagtg 660  
 ggtgcccagg aatgttttaa atctatcagg cacactataa agctggtggt ttcttcctac 720  
 caagtggatt cggcatatga accacctact caatacttta tattttgtct gtttaaaccac 780  
 tgaactctgg tgttgacagg tacaaggag aagagatggg gactgtgaag aggggagggc 840  
 ttccctcatc ttctcacaaga tctttgtttc cataaactat gcagtcataa ttgagaaaaa 900  
 25 gcaatagatg gggcttctta ccatttgttg gttattgctg gggtagcca ggagcagtgt 960  
 ggatggcaaa gtaggagaga ggcccagagg aaagcccac tccctccagc tttgggtct 1020  
 ccagaaagag gctggatttc tgggatgaag cctagaaggc agagcaagaa ctgttccacc 1080  
 aggtgaacag tctacctgc ttggtacat agtccctcaa taagattcag aggaagaagc 1140  
 30 ttatgaaact gaaaatcaaa tcaaggtatt gggagaata atttccctc gattccacag 1200  
 gagggaaagc cacacaatat cattgtgctg gggctcccca aggccctgcc acctggcttt 1260  
 acaaatcatc aggggttgcc tgettggcag tcacatgctt ccctggtttt agcacacata 1320  
 caaggagttt tcagggaaact ctatcaagcc ataccaaaat cagggtcaca tgtgggtttc 1380  
 ccctttcctt gcctcttcat aaaagacaac ttggcttctg aggatggtgg tcttttgcat 1440  
 35 gcagtggggc tgacctgaca aagccccag tttcctgtgg caggttctgg gagaggatgc 1500  
 attcaagctt ctgcagccta ggggacagg ctgcttgctt agttattact gcctcgagc 1560  
 tccaaatccc accaaagtcc tgactccagg tctttcctaa tgcacagtag tcagtctcag 1620  
 cttcggcagt attctcggct gtatgttctc tggcagagag aggcagatga acatagtttt 1680  
 agggagaaag ctgatgggaa acctgtgagt taagccacat gtctcaccag gaataattta 1740  
 40 tgccaggaaa ccaggaaagtc attcaagttg ttctctgagg ccaaagacac tgagcacagc 1800  
 ccagagccaa taaaagatct ttgagtctct ggtgaattca cgaagtgacc ccagctttag 1860  
 ctactgcaat tatgattttt atgggacagc aatttcttgc atctctacag aggaagaaga 1920  
 gggggagtgg gaggggaagg aaagagaaca gagcggcact gggatttgaa aggggaacct 1980  
 ctctatctga ggagcccca ctggcttcag aagcaactta ccaaggggta tttaaagaca 2040  
 45 tgaaaatttc cagaaatacc atttgggtgca tccctttgtt tctgtaatat taaactcagg 2100  
 tgaaattata ctctgacagt ttctctcttt ctgcctcttc cctctgcaga gtcaggacct 2160  
 gcagaactgg ctgaaacaag atttcatggt gtcacccatg agagatgact caatgccaag 2220  
 gcctgaagtt atagatggtt tacagcgtg cgcataattca ggggtcatcg ccaactggct 2280  
 tcgagttcca aagctctgat gaagaaacaa gactccttga tgtgttactg atcccactga 2340  
 50 ttccaggagt caagattagc caggaagcca aacaccagga gttgggggtg cacgtcacca 2400  
 gtccagagcc ctgccacgga tgtacgcagg agcccagcat taggcaatca ggagccagaa 2460  
 catgatcacc agggccacaa ataggaagag gcgtgacagg aactgctcgt ccacatacct 2520  
 ggggtgtcc

<210> 48  
 <211> 1553  
 <212> DNA  
 <213> Human

<400> 48

60 tttttttttt tttttgattt ctgggacaat taagctttat ttttcatata tatatatatt 60  
 tcatatatata tatatatata catatataaa ggaacaattt tgcaaattha cacacctgac 120  
 aaaaccatat atacacacat atgtatgcat acacacagac agacacacac acccgaagct 180  
 65 ctagccaggc cgtttttcca tccctaagta ccattctctc atttgggccc ttctagggtt 240  
 ggggccctga gcttggtttg tagaagtttg gtgctaatat aaccatagct ttaatcccca 300  
 tgaaggacag tgtagacctc atctttgtct gctccccgct gcctttcagt tttacgtgat 360

5 ccatcaagag ggctatggga gccaaagtga caggggggat tgaggctaata tcacctgaac 420  
 tcaaaaacag cgcccagctt cctcaccgca ggcacgcgtc ttttcttttt ttttcctcga 480  
 gacggagtct cgctgtgttg cccaggctgg agtgcagtgg cacggtctcg gctcactgca 540  
 agctccacct cctggattca taccattctc ctgcttcagc cttccgagta gctgggacta 600  
 taggtgccaa ccactacgcc tagctaattt tttttgtat ttttagtaga gacagggttt 660  
 caccgtgtta gccaggatgg tctcgtcctg actttgtgat ccgcccgcct cggcctccca 720  
 aagtgtctgg attacaggcg tgagccacca cacctggccc cggcacgtat cttttaagga 780  
 atgacaccag ttcctggctt ctgaccaaag aaaaaatgtc acaggagact ttgaagaggc 840  
 10 agacaggagg gtggtggcag caacactgca gctgcttctg gatgctgctg ggggtgctctc 900  
 cggagcgggt gtgaacagcg cacttcaaca tgagcaggcg cctggctccg gtgtgtcctc 960  
 acttcagtgg tgcacctgga tgggtggaagc cagccttttg ggcaggaaac cagctcagag 1020  
 aggctacca gctcagctgc tggcaggagc cagggtattta cagccataat gtgtgtaaag 1080  
 aaaaaacacg ttctgcaaga aactctccta cccgctcggg agactggggc tccttgcttg 1140  
 ggatgagctt cactcaacgt ggagatgggt gtggactggg ccctgaaaag cgggccttgc 1200  
 15 agggccaagt agggctccta ggtcctaac ccagtggccc tctgaaaggg ggtgtgcagg 1260  
 cgaggggagc agaggcttc tctctagtcc ctttgaggc tttggctgag agaagagtga 1320  
 gcagggagct gggaatggtc caggcaggga agggagctga agtgattcgg ggctaatagcc 1380  
 tcagatcgat gtatttctct ccctggctct ccggagccct cttgtcaccg ctgctgccct 1440  
 gcaggaggcc catctcttct gggagcttat ctgacttaac ttcaactaca agttcgctct 1500  
 20 tacgagaccg ggggtagcgt gatctcctgc ttccctgagc gcctgcacgg cag

&lt;210&gt; 49

&lt;211&gt; 921

&lt;212&gt; DNA

25 &lt;213&gt; Human

&lt;400&gt; 49

30 ctgtggtccc agctactcag gaggtgagg cgggaggatt gcttgagccc aggagttgga 60  
 tggtgcagtg agccaagatc gcaccattgc cctccactct gggccacgga gcaataccct 120  
 gtctcagaaa acaaaacaaca aaaagcagaa acgctgaagg ggtcggttta cgggaaaacc 180  
 gcctgtcaga acacttggtt actcctaccc cagatcagtg gacctgggaa tgagggttgg 240  
 tcccgggagg cttttctcca agctgttgcc accagaccgg ccatgggaac cctggccaca 300  
 35 gaagcctccc ggggagtggg ccagagcctg gaccgctgtg ctgatgtgtc tggggtggag 360  
 ggaggggtggg gagtgtgcaa ggggtgtgtg gtgcccgggg ggtgttcatt ggcaagcatg 420  
 tgctgcccctg tgtgtgtgcg tgcccctccc ctgcagcgt cgggtggatc tccctccagc 480  
 cccttcgcca ccttctgagc attgtctgtc cacgtgagac tgcccagaga cagcagagct 540  
 ccacgtgggt ttaaggggag acctttccct ggacctgggg gtctcgcctg atctcatgac 600  
 40 caggtgctaa atgaccgac atgcatcacc tgcctttcga tgaccaacct cctgtcccc 660  
 gtcccgtga cctgcccccg tggcgtctca cgggtgatcc tgctcctgac attggtgttc 720  
 actgtagcaa actacattct ggatgggaat ttcatgtac atgtgtggca tgtggaaaat 780  
 ttcaataaaa atggacttga tttagaaagc caaaaagctg tgtggtcctt ccagcacgga 840  
 tactttgacc tcttgctac aacccttccc ttgggtccga ggctggtagc tttgttact 900  
 45 tcagatgggt gggggcgggt g

&lt;210&gt; 50

&lt;211&gt; 338

&lt;212&gt; DNA

50 &lt;213&gt; Human

&lt;400&gt; 50

55 atgatctatc tagatgccct accgtaaaat caaaacacaa aaccctactg actcattccc 60  
 tcccttccag atattacccc atttctctac ttcccattgt agccaaactt tccaaaaatt 120  
 catgttctgt cttcatttcc tcatgttcaa cccaccctgt cttagctacc acccctcagt 180  
 aacgacctag cctgggtaga aacaaatgtc agcatgatac catactcaat gatccttcgt 240  
 cactgttgtc attgtcatca ttccatggcc ttactttccc tctcagcgcc atttgctaca 300  
 gtaagaaact ttctttcttg aattcttggg tctcttgg

60 &lt;210&gt; 51

&lt;211&gt; 1191

&lt;212&gt; DNA

&lt;213&gt; Human

65 &lt;400&gt; 51

5 ctagcaagca ggtaaacgag ctttgtacaa acacacacag accaacacat ccgggggatgg 60  
 ctgtgtgttg ctagagcaga ggctgattaa acactcagtg tgttggctct ctgtgccact 120  
 cctggaaaaat aatgaattgg gtaaggaaca gttataaga aaatgtgcct tgctaactgt 180  
 gcacattaca acaaagagct ggcagctcct gaaggaaaag ggcttgtgcc gctgccgttc 240  
 aaacttgtca gtcaactcat gccagcagcc tcagcgtctg cctccccagc acaccctcat 300  
 tacatgtgtc tgtctggcct gatctgtgca tctgctcgga gacgctcctg acaagtcggg 360  
 aatttctcta tttctccact ggtgcaaaga gcggatttct ccctgcttct cttctgtcac 420  
 ccccgtcct ctcccccagg aggtccttgg atttatggta gctttggact tgcttccccg 480  
 10 tctgactgtc tttgacttct agaattggaag aagctgagct ggtgaaggga agactccagg 540  
 ccatcacaga taaaagaaaa atacaggaag aaatctcaca gaagcgtctg aaaatagagg 600  
 aagacaaact aaagcaccag catttgaaga aaaaaggcctt gagggagaaa tggcttctag 660  
 atggaatcag cagcggaaaa gaacaggaag agatgaagaa gcaaaatcaa caagaccagc 720  
 accagatcca ggttctagaa caaagtatcc tcaggcttga gaaagagatc caagatcttg 780  
 aaaaagctga actgcaaate tcaacgaagg aagaggccat tttaaaagaaa ctaaagtcaa 840  
 15 ttgagcggac aacagaagac attataagat ctgtgaaagt ggaaagagaa gaaagagcag 900  
 aagagtcaat tgaggacatc tatgctaata tccctgacct tccaaagtcc tacatacctt 960  
 ctaggttaag gaaggagata aatgaagaaa aagaagatga tgaacaaaat aggaaagctt 1020  
 tatatgccat ggaaattaaa gttgaaaaag acttgaagac tggagaaagt acagttctgt 1080  
 20 cttccaatac ctctggccat cagatgactt taaaagggtac aggagtaaaa gtttaagatg 1140  
 atgggcaaaa gtccagtgtg ttcagtaaaag tgctaatacac aagttggagg t

&lt;210&gt; 52

&lt;211&gt; 1200

&lt;212&gt; DNA

25 &lt;213&gt; Human

&lt;400&gt; 52

30 aacagggaact ctcaactctat caaccccagg ctggagtcag gtgcgcccac cctgggtccc 60  
 tgcaacctcc gccctccagg ctcaagcaac tctcctgcct cagtcgctct agtagctggg 120  
 actacaggca cacaccacca tgcccagcca atttttgcct tttttgtaga gacagggttt 180  
 cgccttctgt ccaggccggc atcatatact ttaaatacatg ccagatgac tttaatacct 240  
 aatacaatat atcaggttgg tttaaaaata attgcttttt tattattttt gcatttttgc 300  
 35 accaacccta atgctatgta aatagttggt atactgttgc ttaacaacag tatgacaatt 360  
 ttggcttttt ctttgtatta ttttgtattt ttttttttta ttgtgtgggc tttttttttt 420  
 ttctcagtgt tttcaattcc tccttggttg aatccatgga tgcaaaaccc acagatatga 480  
 agggctggct atatatgcat tgatgattgt cctattatat tagttataaa gtgtcattta 540  
 atatgtagtg aaagtatatg tacagtggaa agagttagtg aaaacataaa catttgacc 600  
 40 tttcaagaaa ggtagcttgg tgaagttttt caccttcaaa ctatgtccca gtcagggtc 660  
 tgctactaat tagctataat ctttgcacaa attacatcac ctttgagtct cagttgcctc 720  
 acctgtaaaa tgaaagaact ggatactctc taaggctact tccagccctg tcattctata 780  
 actctgttat gctgaggaag aaattcacat tgtgttaact gtatgagtca aactgaaaat 840  
 gattattaaa gtgggaaaaa gccaattgct tctcttagaa agctcaacta aatttgagaa 900  
 45 gaataatctt ttcaattttt taagaattta aatattttta agggtttgac ctattttatt 960  
 agagatgggg tctcactctg tcacccagac tggagtacag tggcacaatc atagctcact 1020  
 gtgcctcaa attcatgggc tcaagtgate ctctgctc tgccctcaga gtagctgcga 1080  
 ctatgggcat gtgccaccac gcctggctaa catttgtatt gacctattta tttattgtga 1140  
 tttatatctt tttttttttt tctttttttt ttttttataa aatcagaaat acttattttg 1200

50 &lt;210&gt; 53

&lt;211&gt; 989

&lt;212&gt; DNA

&lt;213&gt; Human

55 &lt;400&gt; 53

60 aagccaccac tcaaaacttc ctatacattt tcacagcaga gacaagtga catttatttt 60  
 tatgcctttc ttcctatgtg tatttcaagt ctttttcaaa acaaggcccc aggactctcc 120  
 gattcaatta gtcttgggc tggtcgactg tgcaggagtc caggagacct ctacaaatgc 180  
 agagtgaact tttaccaaca taaaccctag atacatgcaa aaagcaggac ccttctcca 240  
 ggaatgtgcc atttcagatg cacagcacc atgcagaaaa gctggaattt tccttggaac 300  
 cgactgtgat agaggtgctt acatgaacat tgctactgtc tttctttttt tttgagacag 360  
 gtttcgcttg tgcccaggct gagtgaatg cgtgatctca ctactgcaa ttccacctcc 420  
 65 aggttcaagc atttctctgc tcagcctcct agtagctggg ttacaggcac tgccaccatg 480  
 ccggctaatt ttgtattttt gttagatggg atttctccat ttggtcaggc ggtctcgaa 540  
 cccaacctca gtgatctgcc acctcagcct cctaagtgtt ggattacagg atgagccacc 600

	cgaccggcca	ctactgtctt	tctttgaccc	ttccagtttc	gaagataaag	aggaaataat	660
	ttctctgaag	tacttgataa	aatttccaaa	caaaacacat	gtccacttca	ctgataaaaa	720
	atttaccgca	gtttggcacc	taagagtatg	acaacagcaa	taaaaagtaa	tttcaaagag	780
5	ttaagatttc	ttcagcaaaa	tagatgattc	acatcttcaa	gtcctttttg	aaatcagtta	840
	ttaatattat	tctttcctca	tttccatctg	aatgactgca	gcaatagttt	tttttttttt	900
	tttttttttt	ttgcgagatg	gaatctcgct	ctgtcgccca	gcgggagtg	actggcgcaa	960
	gcccggctca	ccgcaatctc	tgccaccgcg				
	<210>	54					
10	<211>	250					
	<212>	DNA					
	<213>	Human					
	<400>	54					
15	catttcccca	ttggtcctga	tggtgaagat	ttagttaaag	aggctgtaag	tcaggttcga	60
	gcagaggcta	ctacaagaag	tagggaatca	agtcctcac	atgggctatt	aaaactaggt	120
	agtggtagg	tagtgaaaaa	gaaatctgag	caacttcata	acgtaactgc	ctttcagggg	180
20	aaagggcatt	ctttaggaac	tgcatctggt	aaccacaccc	ttgatccaag	agctagggaa	240
	acttcagttg						
	<210>	55					
	<211>	2270					
25	<212>	DNA					
	<213>	Human					
	<400>	55					
30	gcgccccga	gcagcgcccg	cgccctccgc	gccttctccg	ccgggacctc	gagcgaaaga	60
	ggcccgcgcg	ccgcccagcg	ctcgctccc	tgcccaccgg	gcacaccgcg	ccgccacccc	120
	gaccccgctg	cgacaggcct	gtccgctgca	caccagcttg	ttggcgctct	cgtcgcgcgcg	180
	ctcgccccgg	gctaactctg	cgcgccacaa	tgagctcccg	catcgccagg	gcgctcgccct	240
	tagtcgacac	ccttctccac	ttgaccaggc	tgggcgctctc	cacctgcccc	gctgcctgcc	300
	actgccccct	ggaggcgccc	aagtgcgcgc	cgggagtcgg	gctgggtccg	gacggctgcg	360
35	gctgctgtaa	ggtctgcgc	aagcagctca	acgaggactg	cagcaaaacg	cagccctgcg	420
	accacaccaa	ggggctggaa	tgcaacttcg	gcgccaagtc	caccgctctg	aaggggatct	480
	gcagagctca	gtcagagggc	agaccctgtg	aatataactc	cagaatctac	caaaacgggg	540
	aaagtttcca	gccaactgt	aaacatcagt	gcacatgtat	tgatggcgcc	gtgggctgca	600
40	ttcctctgtg	tcccaagaa	ctatctctcc	ccaacttggg	ctgtcccaac	cctcggtg	660
	tcaaagttaac	cgggcagtg	tgcgaggagt	gggtctgtga	cgaggatagt	atcaaggacc	720
	ccatggagga	ccaggacggc	ctccttggca	aggagctggg	attcgatgcc	tccgaggtg	780
	agttgacgag	aaacaatgaa	ttgattgcag	ttggaaaagg	cagctcactg	aagcggtcc	840
	ctgttttttg	aatggagcct	cgcatcctat	acaacccttt	acaaggccag	aaatgtattg	900
	ttcaacaac	ttcatggtcc	cagtgtccta	agacctgtgg	aactgggtatc	tccacacgag	960
45	ttaccaatga	caaccctgag	tgccgccttg	tgaaagaaac	ccggatttgt	gaggtgccc	1020
	cttgtggaca	agcagcctga	aaaagggcaa	gaaatgcagc	aagaccaaga	1080	
	aatccccga	accagtcagg	tttacttacg	ctggatgttt	gagtgtgaag	aaataccggc	1140
	ccaagtactg	cggttcctgc	gtggacggcc	gatgctgcac	gccccagctg	accaggactg	1200
	tgaagatg	gttccgctgc	gaagatgggg	agacattttc	caagaacgtc	atgatgatcc	1260
50	agtccctgcaa	atgcaactac	aactgcccgc	atgccaatga	agcagcgttt	cccttctaca	1320
	ggctgttcaa	tgacattcac	aaatttaggg	actaaatgct	acctgggttt	ccagggcaca	1380
	cctagacaaa	caagggagaa	gagtgtcaga	atcagaatca	tgagagaaat	gggcgggggt	1440
	ggtgtgggtg	atgggactca	ttgtagaaag	gaagccttgc	tcattcttga	ggagcattaa	1500
	ggtatttcga	aactgccaag	ggtgctggtg	cggtgggaca	ctaagtcagc	cacgattgga	1560
55	gaatactttg	cttcatagta	ttggagcaca	tgttactgct	tcatttttga	gcttgtggag	1620
	ttgatgactt	tctgttttct	gtttgtaaat	tatttgctaa	gcatattttc	tctaggcttt	1680
	tttccttttg	gggtttctaca	gtcgtaaaag	agataataag	attagttgga	cagtttaaag	1740
	cttttatctg	tccttttgaca	aaagtaaatg	ggagggcatt	ccatcccttc	ctgaaggggg	1800
	acactccatg	agtgtctgtg	agaggcagct	atctgcactc	taaactgcaa	acagaaatca	1860
60	ggtgttttaa	gactgaatgt	tttattttatc	aaaatgtagc	ttttggggag	ggaggggaaa	1920
	tgtaatactg	gaataatttg	taaagtattt	taattttata	ttcagtga	agattttatt	1980
	tatggaatta	accattta	aaagaaatat	ttacctata	tctgagtgt	tgccattcgg	2040
	tatttttaga	ggtgctccaa	agtcattagg	aacaacctag	ctcacgtact	caattattca	2100
	aacaggactt	attgggatac	agcagtgaat	taagctatta	aaataagata	atgattgctt	2160
65	ttataccttc	agtagagaaa	agtcttttga	tataaagtaa	tgtttaaaaa	acatgtattg	2220
	aacacgacat	tgtatgaagc	acaataaaga	ttctgaagct	aaaaaaaaa		

<210> 56  
 <211> 1636  
 <212> DNA  
 <213> Human

<400> 56

```

10  cttgaatgaa gctgacacca agaaccgcgg gaagagcttg ggcccaaagc aggaaagggg 60
    agcgctcgag ttggaagga accgctgctg ctggccgaac tcaagcccgg gcgccccac 120
    cagtttgatt ggaagtccag ctgtgaaacc tggagcgctg ccttctcccc agatggctcc 180
    tggtttgctt ggtctcaagg acactgcatc gtcaaactga tcccctggcc gttggaggag 240
    cagttcatcc ctaaagggtt tgaagccaaa agccgaagta gcaaaaatga gacgaaaggg 300
15  cggggcagcc caaaagagaa gacgctggac tgtggtcaga ttgtctgggg gctggccttc 360
    agcccggtggc cttccccacc cagcaggaag ctctgggcac gccaccaccc ccaagtgcc 420
    gatgtctctt gctgtgttct tgctacggga ctcaacgatg ggcagatcaa gatctgggag 480
    gtgcagacag ggctcctgct tttgaatctt tccggccacc aagatgtcgt gagagatctg 540
    agcttcacac ccagtggcag tttgattttg gtctccgcgt cacgggataa gactcttcgc 600
    atctgggacc tgaataaaca cggtaaacag attcaagtgt tatcggggcca cctgcagtgg 660
20  gtttactgct gttccatctc ccagactgc agcatgctgt gctctgcagc tggagagaag 720
    tcggctcttc tatggagcat gaggtcctac acgttaattc ggaagctaga gggccatcaa 780
    agcagtgttg tctctgtga cttctcccc gactctgccc tgcttgtcac ggcttcttac 840
    gataccaatg tgattatgtg ggacccttac accggcgaaa ggctgagggtc actccaccac 900
    acccaggttg accccgccat ggatgacagt gacgtccaca ttagctcact gagatctgtg 960
25  tgcttctctc cagaaggctt gtaccttgcc acggtggcag atgacagact cctcaggatc 1020
    tgggccctgg aactgaaaac tcccattgca tttgctccta tgaccaatgg gctttgctgc 1080
    acattttttc cacatgggtg agtcattgcc acagggacaa gagatggcca cgtccagttc 1140
    tggacagctc ctagggctct gtccctcactg aagcacttat gccggaaagc ccttcgaagt 1200
    ttcttaacaa cttaccaagt cctagcactg ccaatcccca agaaaatgaa agagttcctc 1260
30  acatacagga ctttttaagc aacaccacat cttgtgtctt tttgtagcag ggtaaatcgt 1320
    cctgtcaaaag ggagtgtctg gaataatggg ccaaaccatc ggtcttgcac tgaatatagca 1380
    tttctttggg attgtgaata gaatgtagca aaaccagatt ccagtgtaca taaaagaatt 1440
    tttttgtctt taaatagata caaatgtcta tcaactttaa tcaagttgta acttatattg 1500
    aagacaattt gatacataat aaaaaattat gacaatgtcc tgggaaaaaa aaaatgtaga 1560
35  aagatggtga aggtgggat ggatgaggag cgtggtgacg ggggcctgca gcgggttggg 1620
    gacctgtgc tgcgtt
  
```

<210> 57  
 <211> 460  
 <212> DNA  
 <213> Human

<400> 57

```

45  ccatgtgtgt atgagagaga gagagattgg gagggagagg gagctcacta gcgcatatgt 60
    gcctccaggg ggctgcagat gtgtctgagg gtgagcctgg tgaaagagaa gacaaaagaa 120
    tggaatgagc taaagcagcc gcctggggtg ggaggccgag cccatttgta tgcagcagg 180
    ggaggagcc cagcaaggga gcctccattc ccaggactct ggaggagct gagaccatcc 240
    atgcccgcag agccctccct cacactccat cctgtccagc cctaattgtg caggtgggga 300
50  aactgaggct ggggaagtcac atagcaagtg actggcagag ctgggactgg aaccacaacca 360
    gcctcctaga ccacggttct tccatcaat ggaatgctag agactccagc caggtgggta 420
    ccgagctcga attcgtaatc atggtcatag ctgtttcctg
  
```

<210> 58  
 <211> 1049  
 <212> DNA  
 <213> Human

<400> 58

```

60  atctgatcaa gaatacctgc cctggctact ctgcggatgt ttctgtccac ttgttcacat 60
    tgaggacca gatatacctt tttacagagg cacttggtcg gtctaacaca gacacctcca 120
    tgacgacatg ctggctcaca ttttgagtt ctgcagaagt cccctcccca gcctggacta 180
    cagcagcact ttcccggtgg ggtgcagtag ccgtttcgac agagcctgga gcactctgaa 240
65  gtcagtgtct gtgcaggttg taccgtggct ctgcattcct caggcattaa aggtcttttg 300
    ggatctacaa ttttgtagag ttttccattg tgagtctggg tcatactttt actgcttgat 360
  
```

5    aaaaatgtaaa cttcacctag ttcattcttct ccaaattccca agatgtgacc ggaaaagtag 420  
       cctctacagg acccactagt gccgacacag agtgggttttt cttgccactg ctttgtcaca 480  
       ggacttttgct ggagagtttag gaaattccca ttacgatctc caaacacgta gcttccatac 540  
       aatctttctg actggcagcc ccggtatata tcataatctt tcccctttat tatctgtaga 600  
       ggcttgaatt ctaaaagtga tggtcactt    tcataatctt tcccctttat tatctgtaga 660  
       attctggctg atgatctgtt ttttccattg gagtctgaac acagtatcgt taaattgatg 720  
       tttatatcag tgggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780  
       aacacttcgg ggggctgggt ggtgctgttg aagtgtgggt tgctccttgg tatggaataa 840  
 10    ggcacgttgc acatgtctgt gtccacatcc agccgtagca ctgagcctgt gaaatcactt 900  
       aaccatcca tttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960  
       aaaaaccgct cagggccaaa gagcagttgc cctcccagat gctttctgtg gagtctctga 1020  
       acttcaagaa agactctggc tgttctcaa

15    <210> 59  
       <211> 747  
       <212> DNA  
       <213> Human

20    <400> 59

25    tttttcaaatt cacatatggc ttctttgacc ccatcaaata actttattca cacaacgctc 60  
       ccttaattta caaagcctca gtcattcata cacattaggg gatccacagt gttcaaggaa 120  
       cttaaatata atgtatcata ccaaccgaag taaaccaagt acaaaaaata ttcataataa 180  
       gttggttcaca cgtaggctct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240  
       atagatttat taactagtat tggaaactaa ctttgtgcct ggcttaaaac ctccctcacg 300  
       ctcgtctgtc ccacacaaat gtttaagaag tcaactgcaat gtactccccg gctctgatga 360  
       aaagaagccc ctggcacaaa agattccagt gcccctgaag aggctccctt cctcctgtgg 420  
       gctctectag aaaaccagcg ggacggcctc cctgctgata ccgtctataa ccttaggggg 480  
       ccctcgggca ggcaacggca gtggactcat ctcggtgatg gctgtagatg ctaacactgg 540  
 30    ccaattcaat gccacaccta ctggttaccc tttaggggca tttctccaga cagaagcccc 600  
       ttgaagccta ggtagggcag gatcagagat acaccgtgt ttgtctcgaa gggctccaca 660  
       gcccagtagc acatgcttgc agaagtagta tctctggact tctgcctcca gtcgaccggc 720  
       cgcgaaattta gtagtaatag cggccgc